Document:

csmo_ex101.htm

EXHIBIT 10.1
  
 DATED 30th DAY OF SEPTEMBER, 2018
  
 ABBYDALE MANAGEMENT LIMITED
  
 and
  
 COSMOS HOLDINGS INC. (Ex PRIME ESTATES & DEVELOPMENTS, INC.)
  
 SHARE PURCHASE AGREEMENT
  
  	 
	1
	 
 
	 

  
 THIS AGREEMENT is made on the 30th day of September, 2018 BETWEEN:
  
  	(1)	ABBYDALE MANAGEMENT LIMITED, a company incorporated on 28/02/2018 pursuant to the laws of Belize, with registration number 169,928, having its registered office at Suite 102, Ground Floor, Corner of Eyre & Hutson Streets, Blake Building, Belize City, Belize (hereinafter called "the Purchaser")

  
 AND
  
  	(2)	COSMOS HOLDINGS INC. (Ex PRIME ESTATES & DEVELOPMENTS, INC.), a company incorporated pursuant to the laws of United States of America, with Business Identification number NV20091458416, having its registered office at Baring Blvd, 1955, Corporate Administrative Services Inc, Sparks, NV89434 Nevada, USA, having its offices at 141 West Jackson Blvd, Suite 4236, Chicago, IL, USA (hereinafter called the "Seller")

  
 WHEREAS:
  
  	(A)	The Seller holds the beneficial interest in 5000 ordinary shares of nominal value EUR 1 each in and corresponding to 100% of the issued share capital of the registered Cyprus company AMPLERISSIMO LTD (hereinafter called the "Company"), under registration number HE 215070, having its registered office at 16, Krinon, 3110 Limassol, Cyprus;
	  
	  

	(B)	the Seller has agreed to sell to the Purchaser the Sale Shares in the share capital of the Company and the Purchaser has agreed to purchase the Sale Shares upon the terms hereinafter appearing.

  
 IT IS HEREBY AGREED as follows:
  
  	1.	DEFINITIONS AND RULES OF CONSTRUCTION

  
  	  
	1.1	DEFINITIONS
	  
	  
	  

	  
	  
	 In this Agreement, unless the context otherwise requires, the following terms shall have the meanings assigned to them below:
  
 "Sale Shares" means 5000 ordinary shares of nominal value EUR 1 each held by the Seller in the share capital of the Company constituting 100% of the issued share capital of the Company.
  
 "Day" or "days" means working days.
  
 "EUR" means EURO, the currency of the European Union.

	  
	  
	  

	  
	 1.2 
	 RULES OF CONSTRUCTION

	  
	  
	  

	  
	  
	 The terms defined in this Agreement shall include the plural as well as the singular form of such defined terms, and the use of any gender herein shall be deemed to include the other gender.

  
  	 
	2
	 
 
	 

  
  	2.	SALE OF SHARES / COMPLETION

  
  	  
	2.1	With this Agreement the Seller sells to the Purchaser, and the Purchaser purchases from the Seller, the Sale Shares free from all charges or liens or any other encumbrances (whether known about or not) and with all rights attaching thereto. The agreed price is €5000, which the Purchaser undertakes to pay to the Seller within five days from signing this Agreement.
	  
	  
	  

	  
	2.2	The Seller and the Purchaser hereby expressly and unequivocally declare that the beneficial interest in the Sale Shares is transferred today from the Seller to the Purchaser absolutely with no reservation or hindrance of any kind and that both parties will exercise all necessary documents for transferring the Sale Shares to the Purchaser.

  
  	3.	COMPLETION
	  
	  

	  
	 With the execution of this Agreement the sale of the Sale Shares is considered completed. The Seller shall deliver or procure delivery to the Purchaser of such documents as may be necessary to transfer to the Purchaser the full beneficial ownership of the Sale Shares.

  
  	4.	WARRANTIES AND REPRESENTATIONS
	  
	  

	  
	 The Seller hereby warrants and represents to the Purchaser in the terms set out in The Schedule annexed to this Agreement, and the Purchaser enters into this Agreement relying upon the same.

  
  	5.	GENERAL PROVISIONS

  
  	  
	5.1	NOTICES
	  
	  
	  

	  
	  
	 All notices and other communications hereunder by a Party hereto shall be written in English and (a) delivered in person or (b) transmitted by facsimile (in which case the sender shall simultaneously telephone the addressee and confirm receipt and send by recorded letter a copy) to the addressee at the address provided herein or at such other address as may have been specified by like notice:

	  
	  
	  

	  
	  
	 The Seller: 
 COSMOS HOLDINGS INC. (Ex PRIME ESTATES & DEVELOPMENTS, INC.) 
 141 West Jackson Blvd, Suite 4236, Chicago, Illinois, USA.
  
 The Purchaser: 
 ABBYDALE MANAGEMENT LIMITED 
 Suite 102, Ground Floor, Corner of Eyre & Hutson Streets, Blake Building, Belize City, Belize 

	  
	  
	  

	  
	 5.2 
	 FEES AND EXPENSES

	  
	  
	  

	  
	  
	  
 Each one of the Parties respectively shall bear its own external costs incurred in connection with the negotiation, preparation and conclusion of this Agreement, including, without limitation, the costs of all advocates' fees.

	  
	  
	  

	  
	 5.3
	 HEADINGS AND REFERENCES

	  
	  
	  

	  
	  
	 The descriptive headings of the Articles of this Agreement are inserted for convenience only and do not affect the interpretation of this Agreement. All references in this Agreement to an "Article" or "the Schedule" refer to the corresponding Article of or Schedule to this Agreement unless otherwise indicated to the contrary. The Schedule hereto forms part of and is incorporated in this Agreement.

  
  	 
	3
	 
 
	 

  
  	  
	5.4	ENTIRE AGREEMENT
	  
	  
	  

	  
	  
	 This Agreement constitutes the entire agreement and understanding of the Parties hereto in respect of the subject matter contained herein, and there are no restrictions, promises, representations, warranties, covenants, or undertakings with respect to the subject matter hereof, other than those expressly set forth or referred to herein. This Agreement supersedes all prior agreements and understandings between the Parties hereto with respect to the subject matter hereof and thereof.

	  
	  
	  

	  
	 5.5
	 SEVERABILITY

	  
	  
	  

	  
	  
	 The invalidity, illegality or unenforceability of one or more of the provisions of this Agreement in any jurisdiction shall not affect the validity, legality or enforceability of the remainder of this Agreement in such jurisdiction or the validity, legality or enforceability of this Agreement, including any such provision in any other jurisdiction, it being intended that all rights and obligations of the Parties hereto shall be enforceable to the fullest extent permitted by law.

	  
	  
	  

	  
	 5.6
	 SUCCESSORS AND ASSIGNS

	  
	  
	  

	  
	  
	 The provisions of this Agreement shall be binding upon and accrue to the benefit of the Parties hereto and their respective successors and assigns. None of the two Parties hereto may assign its rights or obligations hereunder in whole or in part without the prior written consent of the other Party.

	  
	  
	  

	  
	 5.7
	 AMENDMENTS WAIVERS

	  
	  
	  

	  
	  
	 This Agreement may not be amended, modified or supplemented and no waivers of or consents to or departures from the provisions hereof may be given unless consented to in writing by the two Parties hereto.

	  
	  
	  

	  
	 5.8
	  COUNTERPARTS

	  
	  
	  

	  
	  
	 This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall constitute one and the same Agreement.

	  
	  
	  

	  
	 5.9
	 GOVERNING LAW

	  
	  
	  

	  
	  
	 The construction, validity and performance of this Agreement shall be governed by the Laws of the Republic of Cyprus and all disputes which may arise under, out or in connection with or in relation to this Agreement shall be referred to the exclusive jurisdiction of the Courts of the Republic of Cyprus.
  
 It is provided that any dispute that may arise under the terms and conditions of this Agreement shall first be duly and appropriately referred to Arbitration proceedings in Cyprus and only where such Arbitration proceedings fail to resolve the dispute to the satisfaction of the Parties may the Parties proceed to submit an application in the competent courts of Cyprus.

	  
	  
	  

	  
	 5.10
	 ALL TERMS OF ESSENCE OF AGREEMENT 

	  
	  
	  

	  
	  
	 All terms of this Agreement are of the essence.

	  
	  
	  

	  
	 5.11
	 AGREEMENT MADE IN DUPLICATE

	  
	  
	  

	  
	  
	 The present Agreement has been made in duplicate each Party receiving one copy.

  
  	 
	4
	 
 
	 

  
 IN WITNESS WHEREOF this Agreement has been duly executed by the Parties on the date first above written.
  
  	  
	The Seller 	 	 	The Purchaser	 
	  
	  
	  
	  
	  
	  

	  
	 /s/ Grigorios Siokas 
	 	 	 /s/ Matthew Bradley 
	 
	  
	 Grigorios Siokas 
	 	 	 Matthew Bradley
	 
	  
	 CEO and Director of 
	 	 	Director of 	 
	  
	 COSMOS HOLDINGS INC. 
	  
	  
	 ABBYDALE MANAGEMENT LIMITED
	  

	  
	  
	  
	  
	  
	  

	  
	 Witness: 
	  
	  
	 Witness: 
	  

	  
	  
	  
	  
	  
	  

	  
	 Name: 
	  
	  
	 Name: 
	  

	  
	 Passport No: 
	  
	  
	 Passport No: 
	  

  
  	 
	5
	 
 
	 

  
 THE SCHEDULE
  
 The Seller represents and warrants to the Purchaser that
  
  	1.	the Seller is a company duly incorporated under the Laws of United States of America and that it has taken all necessary corporate action to approve and authorize its entry into this Agreement and in the performance of its obligations hereunder;
	  
	  

	2.	the Sale Shares are fully paid;
	  
	  

	3.	it is the absolute beneficial owner of the Sale Shares to be sold by it, and each of the Sale Shares will be free from all charges, liens and encumbrances whatsoever;
	  
	  

	4.	the execution and delivery of this Agreement

  
  	  
	4.1	does not and will not cause the Company or the Seller or either of them to be in breach of any of the terms and provisions of any agreement or arrangement or order or injunction of any Court or competent tribunal;
	  
	  
	  

	  
	4.2	does not and will not relieve any person of or entitle any person to terminate any contractual or other obligation to the Company;

  
  	5.	the information relating to the incorporation, shareholders, officers and other corporate details of each of the Seller and the Company which the Seller or the Company have supplied to the Purchaser or the Purchaser's advocates is true and accurate;
	  
	  

	6.	the Company is a limited liability company duly organized and validly existing under the laws of Cyprus;
	  
	  

	7.	the Company has all authority, licenses and permits necessary to carry out its business and, in particular, has complied in all material respects with the provisions of the Companies Act of Cyprus and all other relevant legislation; and
	  
	  

	8.	the Company does not have any liabilities which have not been disclosed to the Purchaser and that there is no claim, action, suit, proceeding, arbitration, investigation or hearing, pending or threatened by or before any court or governmental or administrative agency or authority or private arbitration tribunal against the Company and that the Company is not a Party to any litigation or arbitration.

  
  	  
	The Seller 	 	 	The Purchaser	 
	  
	  
	  
	  
	  
	  

	  
	 /s/ Grigorios Siokas 
	 	 	 /s/ Matthew Bradley 
	 
	  
	 Grigorios Siokas 
	 	 	 Matthew Bradley
	 
	  
	 CEO and Director of 
	 	 	 Director of 
	 
	  
	 COSMOS HOLDINGS INC. 
	  
	  
	 ABBYDALE MANAGEMENT LIMITED
	  

	  
	  
	  
	  
	  
	  

	  
	 Witness: 
	  
	  
	 Witness: 
	  

	  
	 Name: 
	  
	  
	 Name: 
	  

	  
	 Passport No: 
	  
	  
	 Passport No: 
	  

  
  
  	 6EX-10.9

 Exhibit 10.9 
  

					
	Execution Version 28.11.2016	  		  	CONFIDENTIAL

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH 

“[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE 

SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION 

REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE 

SECURITIES ACT OF 1933, AS AMENDED. 

OXFORD BIOMEDICA (UK) LIMITED 

and 
 ORCHARD
THERAPEUTICS LIMITED 
  
  

LICENCE AND DEVELOPMENT AGREEMENT 
  

 
 ***Confidential Treatment Requested***

  
 Page | 1 

			
	28.11.2016	  	CONFIDENTIAL

  

 Contents 
  

							
	Clause No.	 	 	  	Page No.	 
			
	 1.
	 	Definitions and Interpretation	  	 	3	 
			
	 2.
	 	Management of the Collaboration	  	 	10	 
			
	 3.
	 	Grant of Rights	  	 	12	 
			
	 4.
	 	Collaboration	  	 	15	 
			
	 5.
	 	Collaboration Intellectual Property	  	 	17	 
			
	 6.
	 	Equity and Royalties	  	 	28	 
			
	 7.
	 	Records and Audit	  	 	20	 
			
	 8.
	 	Confidential Information	  	 	21	 
			
	 9.
	 	Warranties and Liability	  	 	24	 
			
	 10.
	 	Duration and Termination	  	 	25	 
			
	 11.
	 	Liability and Indemnities	  	 	28	 
			
	 12.
	 	General	  	 	30	 
		
	 Schedule 1 : BioMedica Background IPR
	  	 	34	 
		
	 Schedule 2 : APPROVED SUBCONTRACTORS
	  	 	36	 
		
	 Schedule 3 : MILESTONES
	  	 	37	 
		
	 Schedule 4 : AGREED FORM PRESS RELEASE
	  	 	38	 
		
	 Schedule 5 : COLLABORATION PLAN
	  	 	41	 
		
	 Schedule 6 : EXPERT DETERMINATION PROCEDURE
	  	 	42	 
		
	 Schedule 7 : ORCHARD BACKGROUND PATENTS
	  	 	43	 
		
	 Schedule 8 : KEY TERMS OF PHARMACOVIGILANCE AGREEMENT
	  	 	44	 

  

  
 ***Confidential Treatment
Requested*** 
 Page | 2 

			
	28.11.2016	  	CONFIDENTIAL

  

 BETWEEN:     

 

	(1)	 OXFORD BIOMEDICA (UK) LIMITED, a company incorporated in England and registered under number 03028927,
whose registered office is at Windrush Court, Transport Way, Oxford, OX4 6LT (“BioMedica”); and 

  

	(2)	 ORCHARD THERAPEUTICS LIMITED, a company incorporated in England and registered under number 09759506,
whose registered office is at Octagon Point, 5 Cheapside, London, EC2V 6AA (“Orchard”). 

 BACKGROUND: 

 

	(A)	 BioMedica has special expertise and longstanding experience in the field of lentiviral vector gene therapy
products including manufacture, testing and product release. 

  

	(B)	 BioMedica has developed and controls certain intellectual property rights useful for the production and use of
lentiviral vectors in human cells. 

  

	(C)	 Orchard wishes to develop and commercialise certain gene therapy products transduced using lentiviral vectors
for the treatment of adenosine deaminase severe combined immunodeficiency and other diseases. 

  

	(D)	 Orchard wishes to appoint BioMedica to perform development activities and to manufacture and supply certain of
Orchard’s requirements of lentiviral vectors. Orchard also wishes to take a licence under certain intellectual property of BioMedica on the terms of this Agreement. 

OPERATIVE PROVISIONS 
  

	1.	 Definitions and Interpretation 

 

	1.1	 Definitions. In this Agreement, the following words and expressions shall have the following meanings:

  

	 	(a)	 “Accounting Standards” means internationally recognised accounting principles (e.g. IFRS,
US GAAP, etc.) in each case, as generally and consistently applied throughout Orchard’s organisation; 

  

	 	(b)	 “ADA-SCID” means adenosine deaminase severe combined
immunodeficiency;  

  

	 	(c)	 “Affiliate” means with respect to a Party, any other Person that directly or indirectly,
controls, is controlled by or is under common control with such Party; in this context, “control”, and with correlative meanings, “controlled by” and “under common control with”, shall mean ownership of fifty per cent
(50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty per cent (50%) or more of the equity interest in the case of any other type of legal entity, status as a general partner in
any partnership, or any other arrangement whereby the Person controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity, or the ability to cause the direction of the management or
policies of a corporation or other entity. In the case of entities 

  
 ***Confidential Treatment
Requested*** 
 Page | 3 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	
organised under the laws of certain countries, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty per cent (50%), and in such case such lower
percentage shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management and policies of such entity; 

 

	 	(d)	 “Applicable Laws” means any law (including common law or other binding law), statute,
regulation, code, directive or any requirement of a Competent Authority; 

  

	 	(e)	 “BioMedica Arising IPR” means all Intellectual Property Rights and materials prepared,
developed, generated or derived by or on behalf of either Party in the course of the performance of its obligations under the Collaboration Plan, the Letter of Intent, or the Supply Agreement; 

 

	 	(f)	 “BioMedica Background IPR” means the patents and patent applications listed in Schedule 1;

  

	 	(g)	 “Business Day” means Monday to Friday (inclusive) except bank or public holidays in
London, UK; 

  

	 	(h)	 “Charge” has the meaning set forth in clause 12.7(a)(ii); 

 

	 	(i)	 “Claim” means losses, liabilities, damages, reasonable legal costs and other reasonable
expenses of any nature whatsoever suffered or incurred in connection with any Third Party demands, claims, actions, or proceedings (whether criminal or civil, in contract, tort or otherwise); 

 

	 	(j)	 “Collaboration Costs” means the following costs for activities set out in the Collaboration
Plan (as may be amended pursuant to this Agreement): 

  

	 	(i)	 the FTE Costs; 

  

	 	(ii)	 Materials Costs; and 

 

	 	(iii)	 Out-of-Pocket Costs;

  

	 	(k)	 “Collaboration Materials” means the materials provided by one Party to the other Party as
-required for the performance of the Collaboration Plan; 

  

	 	(l)	 “Collaboration Particles” means [***] particles for the delivery of specific sequences
into target cells, manufactured by BioMedica and supplied to Orchard by BioMedica, for use in treating any Initial Indication or Subsequent Indication; 

  

	 	(m)	 “Collaboration Plan” means the collaboration plan set out in Schedule 5 as amended from
time to time by the Steering Committee; 

  

	 	(n)	 “Collaboration Product” means any [***] using Collaboration Particles by or on behalf of
Orchard or any of its Affiliates or sublicensees, in each case for use in treating any Initial Indication or Subsequent Indication; 

  

	 	(o)	 “Collaboration Term” has the meaning set forth in clause 10.1; 

  
 ***Confidential Treatment
Requested*** 
 Page | 4 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(p)	 “Commercialise” means any and all activities directed toward marketing, promoting, detailing,
distributing, importing, exporting, selling or offering to sell a therapeutic product or therapy, but excluding all Manufacturing activities in support of the foregoing, and “Commercialisation” and “Commercialising”
shall have a corresponding meaning; 

  

	 	(q)	 “Commercially Reasonable Efforts” means the expenditure of those efforts and resources
normally used by a reasonable Third Party company in the biopharmaceutical industry in pursuing development (including manufacturing and process development) of similar pharmaceutical products with similar market and economic potential, and at a
similar stage in development or product life; 

  

	 	(r)	 “Competent Authority” any local or national agency, authority, department, inspectorate,
minister, ministry official, or public or statutory Person (whether autonomous or not) of any government of any country having jurisdiction over this Agreement or any of the Parties or over the development, Manufacture, sale, or use of medicinal
products, including, where applicable, the European Commission and the European Court of Justice; 

  

	 	(s)	 “Confidential Information” means all information of a confidential or proprietary nature which
is obtained directly or indirectly by one Party (the “Receiving Party”) or its Affiliates, from the other Party (the “Disclosing Party”) or its Affiliates at any time before, on, or after the Effective Date, without
regard to the form or manner in which such information is disclosed or obtained (including information disclosed orally or in documentary or electronic form or by way of model, or obtained by observation), and in addition shall include:

  

	 	(i)	 the existence and terms of this Agreement and the Supply Agreement for which both Parties shall be deemed to be
the Receiving Party; and 

  

	 	(ii)	 information disclosed [***] and with effect from the Effective Date, such information shall be deemed to be
Confidential Information of the relevant Party under this Agreement and subject to the terms of this Agreement; and 

  

	 	(iii)	 the Manufacturing Know-How and BioMedica Arising IPR for which
BioMedica shall be deemed to be the Disclosing Party; and 

  

	 	(iv)	 the Orchard Arising IPR for which both Parties shall be deemed to be the Disclosing Party;

  

	 	(t)	 “Control” and with correlative meaning, “Controlled by”, means with respect
to any Intellectual Property Right or material, the possession (whether by ownership or licence, other than pursuant to this Agreement) by a Party of the legal authority or right to grant to the other Party access and/or a licence as provided herein
under such Intellectual Property Right or in respect of such material without violating the terms of any agreement or other arrangements with any Third Party, or misappropriating the proprietary or trade secret information of a Third Party;

  

	 	(u)	 “Equity” means the fully diluted share capital of Orchard as at the Effective Date;

  
 ***Confidential Treatment
Requested*** 
 Page | 5 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(v)	 “Field” means [***]; 

 

	 	(w)	 “FTE” means a full time equivalent person year (consisting of 224 days at 7 hours per day);

  

	 	(x)	 “FTE Costs” for a given period means the FTE Rate multiplied by the total FTEs
(proportionately, on a per-FTE basis) directly engaged, in the particular period, in the performance of activities pursuant to the Collaboration Plan; 

 

	 	(y)	 “FTE Rate” means [***] (which may be prorated on a daily or hourly basis as necessary). The
FTE Rate is a preferential “fully burdened” rate and covers employee salaries, benefits, and ordinary laboratory consumables; 

  

	 	(z)	 “Fundamental Breach” means a material breach by BioMedica of any material obligation contained
in clauses [***]; 

  

	 	(aa)	 “GBP” and “£” mean the lawful currency of the United Kingdom;

  

	 	(bb)	 “GMP” has the meaning set out in the Supply Agreement; 

 

	 	(cc)	 “[***] Licence” means the licence agreement between BioMedica and [***] dated [***];

  

	 	(dd)	 “Initial Indications” means ADA-SCID and MPS-IIIA; 

  

	 	(ee)	 “Insolvency Event” means, in relation to either Party, any of the following:

  

	 	(i)	 a meeting of creditors of that Party being held or an arrangement or composition with or for the benefit of its
creditors (including a voluntary arrangement as defined in the Insolvency Act 1986) being proposed by or in relation to that Party; 

  

	 	(ii)	 a chargeholder, administrator, receiver, administrative receiver or other similar person taking possession of
or being appointed over or any distress, execution or other process being levied or enforced (and not being discharged within seven days) on that Party or the whole or a material part of the assets of that Party; 

 

	 	(iii)	 that Party ceasing to carry on business or being deemed to be unable to pay its debts within the meaning of
section 123 Insolvency Act 1986 ([***]) or ceasing to pay its debts as they fall due; 

  

	 	(iv)	 that Party or its directors or the holder of a qualifying floating charge or any of its creditors giving notice
of their intention to appoint, appointing or making an application to the court for the appointment of, an administrator; 

  

	 	(v)	 a petition being presented or advertised or a resolution being passed or an order being made for the purposes
of or in relation to the administration or the winding-up, bankruptcy, liquidation or dissolution of that Party; or 

  

	 	(vi)	 the happening in relation to that Party of an event analogous to any of the above in any jurisdiction in which
it is incorporated or resident or in which it carries on business or has assets; 

  
 ***Confidential Treatment
Requested*** 
 Page | 6 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(ff)	 “Intellectual Property Rights” means all rights in patents, rights to inventions, copyright
and related rights, rights in trade marks, trade names and domain names, rights in designs, rights in computer software, database rights, rights in confidential information (including know-how) and any other
intellectual property rights, in each case whether registered or unregistered and including all applications (or rights to apply) for, and renewals or extensions (for their full term) of, such rights and all similar or equivalent rights or forms of
protection which subsist or will subsist now or in the future in any part of the world; 

  

	 	(gg)	 “Letter of Intent” means that letter of intent executed by the Parties on [***];

  

	 	(hh)	 “Loan Agreement” has the meaning set forth in clause 12.7(a)(i); 

 

	 	(ii)	 “Manufacturing” means any and all operations, including without limitation processing,
filling, testing, releasing and packaging for shipment, carried out by or on behalf of BioMedica in the preparation of the Particles under this Agreement, the Supply Agreement and the Quality Agreement; and “Manufacture” and
“Manufactured” have corresponding meanings; 

  

	 	(jj)	 “Manufacturing Know-How” means know-how which is Controlled by BioMedica at the Effective Date and which is used by BioMedica in the course of performance of the activities assigned to it under the Supply Agreement; 

 

	 	(kk)	 “Materials Costs” shall mean the direct cost of materials used by BioMedica in the
performance of the Collaboration Plan; 

  

	 	(ll)	 “Milestone” means the milestones set out in Schedule 3; 

 

	 	(mm)	 “MPS-IIIA” means mucopolysaccharidosis III (or
Sanfilippo syndrome type A);  

  

	 	(nn)	 “Net Sales” means the net sales recorded by Orchard or any of its Affiliates or any
sublicensees (including through multiple tiers), for any Product sold or otherwise supplied to a Third Party, as determined in accordance with the Accounting Standards as consistently applied, of the applicable selling entity. The deductions booked
on an accrual basis by Orchard or any of its Affiliates or sublicensees under the applicable entity’s Accounting Standards to calculate the recorded net sales from gross sales shall be limited to the following: 

 

	 	(i)	 [***]; 

  

	 	(ii)	 [***]; 

  

	 	(iii)	 [***]; 

  

	 	(iv)	 [***]; 

  

	 	(v)	 [***]; 

  

	 	(vi)	 [***]; 

  

	 	(vii)	 [***]; 

  
 ***Confidential Treatment
Requested*** 
 Page | 7 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(viii)	 [***]; and 

  

	 	(ix)	 [***]. 

  

	 	[***];	 

  

	 	(oo)	 “Orchard Arising IPR” means all Intellectual Property Rights and materials prepared,
developed, generated or derived by or on behalf of either Party in the course of the performance of its obligations under the Collaboration Plan, the Letter of Intent or the Supply Agreement solely to the extent that such Intellectual Property
Rights and materials are (i) an improvement to the Orchard Technology and (ii) cannot be exploited without also infringing Orchard Background Patents; 

 

	 	(pp)	 “Orchard Background Patents” means the patents referred to in Schedule 7 to the extent that
such patents claim the Orchard Technology, and any patents issuing therefrom or claiming priority thereto, worldwide, together with any extensions (including patent term extensions and supplementary protection certificates) and renewals thereof,
reissues, reexaminations, substitutions, confirmation patents, registration patents, invention certificates, patents of addition, renewals, divisionals, continuations and continuations in part of any of the foregoing, in each case to the extent that
the same claim the Orchard Technology; 

  

	 	(qq)	 “Orchard Technology” means (i) vectors [***], cells containing the same, and use of the
cells to treat a subject; (ii) vectors for treating ADA-SCID, [***], cells containing the same, and use of the cells to treat ADA-SCID; and (iii) vectors
[***]; 

  

	 	(rr)	 “Other Particles” means [***], manufactured by or on behalf of Orchard or its
Affiliates or sublicensees, for use in treating any indication other than an Initial Indication or Subsequent Indications; 

  

	 	(ss)	 “Other Product” means [***] or any of its Affiliates or sublicensees, in each case for use in
treating any indication other than an Initial Indication or Subsequent Indication; 

  

	 	(tt)	 “Out-of-Pocket
Costs” shall mean all out-of-pocket costs and expenses paid by or on behalf of BioMedica to Third Parties in connection with the performance of activities
pursuant to the Collaboration Plan; 

  

	 	(uu)	 “Particle” means any Collaboration Particle and/or Other Particle; 

 

	 	(vv)	 “Parties” means BioMedica and Orchard and “Party” shall mean either of them;

  

	 	(ww)	 “Person” means any individual, partnership, limited liability company, firm, corporation,
association, trust, unincorporated organisation or other legal entity; 

  

	 	(xx)	 “Product” means any Collaboration Product, and/or Other Product; 

 

	 	(yy)	 “Quality Agreement” has the meaning set out in the Supply Agreement; 

 

	 	(zz)	 “Quarter” means a calendar quarter ending on 31 March, 30 June, 30 September, and 31
December; 

  
 ***Confidential Treatment
Requested*** 
 Page | 8 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(aaa)	 “Representatives” means, in relation to a Party, such Party’s Affiliates, and its and
their directors, officers, employees, consultants, advisors, and permitted subcontractors and in the case of Orchard, its licensees and sublicensees; 

  

	 	(bbb)	 “Share Subscription Letter” means the letter dated on or about the date of this Agreement
relating to the issue to BioMedica of Equity in accordance with clause 6.1; 

  

	 	(ccc)	 “Senior Officers” means, for Orchard, the Chief Executive Officer or a Board Member, and for
BioMedica, the Chief Executive Officer of BioMedica; 

  

	 	(ddd)	 “Steering Committee” means the steering committee to be established, and operating, in
accordance with the provisions of clause 2; 

  

	 	(eee)	 “Subsequent Indications” means an indication added to the scope of this Agreement in
accordance with clauses 4.3 (a) or (b); 

  

	 	(fff)	 “Supply Agreement” means the supply agreement between the Parties relating to the supply by
BioMedica of [***] to Orchard dated on our about the date of this Agreement; 

  

	 	(ggg)	 “Term” means the term of this Agreement; 

 

	 	(hhh)	 “Third Party” means any Person other than a Party or its Affiliates; 

 

	 	(iii)	 “Valid Claim” means a claim of: 

 

	 	(i)	 an unexpired and issued patent; or 

 

	 	(ii)	 a pending patent application; 

that has not been disclaimed, revoked, or held invalid, unpatentable or unenforceable by an administrative agency, court or other government
agency of competent jurisdiction in a final and non-appealable decision (or a decision unappealed within the time limit allowed for appeal), and which has not been admitted to be invalid or unenforceable
through reissue, re-examination or disclaimer or otherwise; and 
  

	 	(jjj)	 “Year” means a period of twelve (12) consecutive calendar months ending on 31 December.

  

	1.2	 Interpretation. In this Agreement: 

 

	 	(a)	 unless otherwise specified, references to clauses and schedules are to the clauses and schedules of this
Agreement; 

  

	 	(b)	 the words “include”, “including” and “in particular” are to be construed as being
by way of illustration or emphasis only and are not to be construed so as to limit the generality of any words preceding them; 

  

	 	(c)	 the words “other” and “otherwise” are not to be construed as being limited by any words
preceding them; 

  
 ***Confidential Treatment
Requested*** 
 Page | 9 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(d)	 headings are used for convenience only and do not affect its interpretation; and 

 

	 	(e)	 a reference to the singular includes a reference to the plural and vice versa and a reference to any gender
includes a reference to all other genders. 

  

	2.	 Management of the Collaboration 

 

	2.1	 Steering Committee. Within [***] days after the Effective Date, the Parties shall establish a steering
committee (“Steering Committee”) by each Party designating its initial members to serve on the Steering Committee and notifying the other Party of its dates of availability for the Steering Committee’s first meeting. The
Steering Committee will remain in place until the termination or expiration of the Collaboration Term and, unless otherwise agreed in writing between the Parties, will be disbanded at the end of such period. 

 

	2.2	 Role of Steering Committee. The Steering Committee shall lead and oversee the collaboration between the
Parties and, subject to clause 2.7, shall be responsible for and have authority over the following: 

  

	 	(a)	 providing a forum for, and facilitating, communications between the Parties with respect to the collaboration
between the Parties; 

  

	 	(b)	 subject to clause 4.2, reviewing and approving any revised Collaboration Plans (which may be conducted by
explicit email exchange); 

  

	 	(c)	 considering expansion of the collaboration between the Parties to indications other than the Initial
Indications as contemplated in clause 4.3; 

  

	 	(d)	 overseeing and monitoring the implementation of the Collaboration Plan by the Parties and coordinating the
activities of the Parties under the Collaboration Plan; 

  

	 	(e)	 determining achievement of the Milestones; and 

 

	 	(f)	 making such other determinations as are expressly delegated to it under the terms of this Agreement.

  

	2.3	 Membership. The Steering Committee shall consist of [***] senior personnel of BioMedica and [***] senior
personnel of Orchard, in each case with authority to make decisions for the appointing Party on issues within the mandate of the Steering Committee. Each member shall have the appropriate background and expertise to contribute to the Steering
Committee. Each Party may change its members on the Steering Committee from time to time. Either Party may, from time to time, invite additional representatives or consultants, who are not Steering Committee members but who have knowledge and/or
experience in relation to the performance of the collaboration between the Parties to attend Steering Committee meetings, subject to the written consent of the other Party (such consent not to be unreasonably withheld or delayed) and such
representatives and consultants being bound by the confidentiality obligations set out in clause 8. 

  

	2.4	 Co-Chairpersons. Each Party shall appoint [***] of its
members to co-chair Steering Committee meetings (each, a “Co-Chairperson”). The Co-Chairpersons shall attend
meetings, ensure the orderly conduct of meetings, and ensure that written minutes of each meeting are taken and issued to each of the Parties. 

  
 ***Confidential Treatment
Requested*** 
 Page | 10 

			
	28.11.2016	  	CONFIDENTIAL

  

	2.5	 Meetings. The Steering Committee shall meet at least [***] times per Year or more or less often as
otherwise agreed by the Steering Committee, but in no event [***]. Such meetings may be conducted by telephone, videoconference or in person as determined by the Co-Chairpersons. Each Party may also call for
special meetings of the Steering Committee with reasonable prior notice (it being agreed that at least [***] Business Days shall constitute reasonable notice), to resolve particular matters within the decision-making responsibility of the Steering
Committee. Meetings of the Steering Committee shall be effective only if at least [***] of each Party is present and participating as a Co-Chairperson. 

 

	2.6	 Decision-Making. The Steering Committee will endeavour to make decisions by consensus of the Co-Chairpersons with each Party having [***] vote. If a dispute or failure to agree arises which cannot be resolved within the Steering Committee the Steering Committee shall cause such dispute or failure to agree
to be referred to the Senior Officers (or their respective delegates) for resolution. The Senior Officers (or their respective delegates) shall attempt in good faith to resolve such dispute or failure to agree. In the event of a dispute as to
whether a Milestone has been achieved or if the Parties are unable to agree on the extension of any Milestone deadline in accordance with clause 4.9, either Party may refer the matter to an expert for determination in accordance with Schedule 6.

  

	2.7	 Limits. The Steering Committee shall only have the powers assigned expressly to it in this Agreement.
Notwithstanding any provision to the contrary, the Steering Committee shall not have any power to amend or modify the provisions of this Agreement, or to waive compliance with this Agreement and each Party shall retain the rights, powers and
discretion granted to it under this Agreement and no such rights, powers or discretion shall be delegated to or vested in the Steering Committee. 

  

	2.8	 Project Leaders. Each Party shall appoint, and notify the other Party of the identity of, a project
leader who will be the primary point of contact for communicating all instructions and information to the other Party (“Project Leader”). The Parties shall procure that the Project Leaders will communicate with each other during the
Collaboration Term, by telephone, email and letter or face-to-face, as often as is reasonably necessary for each Party to update the other on the progress of the
activities under the Collaboration Plan. Each Party may change its Project Leader at any time by giving written notice to the other Party, provided that there shall always be a designated Project Leader for each Party for the duration of the
Collaboration Term and, unless otherwise agreed in writing between the Parties, the Project Leaders will be discharged from such role at the end of the Collaboration Term. 

 

	2.9	 Project Team. On or promptly after the Effective Date, the Parties will also establish a project team
(“Project Team”) which shall consist of the Project Leaders and such other employees, representatives or consultants invited by a Project Leader and approved by the other Party to participate in Project Team meetings. Prior to
attendance of any Project Team meeting all such representatives and consultants must be bound by the confidentiality obligations set out in clause 8. The Project Team shall have operational responsibility for
co-ordinating the performance of the Collaboration Plan. Subject to clause 4.2, the Project Team may also amend the Collaboration Plan and estimated Collaboration Costs, provided such cost changes have been
approved by the appropriately authorized representative of the party paying 

  
 ***Confidential Treatment
Requested*** 
 Page | 11 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	
for such cost change. A copy of the updated Collaboration Plan and details of any changes to the Collaboration Costs shall be submitted to the members of the Steering Committee prior to the next
meeting of the Steering Committee following such agreement of such amendments by the Project Team. The Project Team shall hold meetings on a [***] basis during the performance of the Collaboration Plan, or more or less frequently as determined by
the Project Leaders to be required for co-ordinating and monitoring activities under the Collaboration Plan. Project Team meetings can be held face to face, or by tele- or video-conference, at such times and
places as are agreed to by the Parties. All decisions of the Project Team will be made by consensus of the Project Leaders, and any failure to agree will be referred to the Steering Committee for resolution. 

 

	2.10	 Costs of Governance. The Parties agree that the costs incurred by each Party in connection with its
participation in the Steering Committee shall be borne solely by such Party. 

  

	3.	 Grant of Rights 

 

	3.1	 Licence Grant. BioMedica hereby grants to Orchard, subject to the terms of this Agreement:

  

	 	(a)	 with respect to Collaboration Particles and Collaboration Products a licence under the BioMedica Background IPR
and the BioMedica Arising IPR, which licence shall be: 

  

	 	(i)	 exclusive and worldwide, except that, where such Collaboration Particles and/or Collaboration Products are for
use in treating any Subsequent Indication and such Subsequent Indication is the subject of the [***] Licence: 

  

	 	(A)	 such licence granted by BioMedica to Orchard shall be non-exclusive;
and 

  

	 	(B)	 save in respect of the rights granted to [***] under the [***] Licence [***], BioMedica shall not grant to any
Third Party any rights under the BioMedica Background IPR with respect to such Subsequent Indication; 

  

	 	(ii)	 solely for the purposes of research, development, and Commercialisation (in each case excluding Manufacture of
Collaboration Particles (except as provided in paragraph (iii) below)) of Collaboration Products in the Field; 

  

	 	(iii)	 in the event of a Prolonged Failure to Supply (as defined in the Supply Agreement): 

 

	 	(A)	 the licence granted pursuant to this clause 3.1(a) shall be extended to include the Manufacture of
Collaboration Particles and clause 3.1(a)(ii) shall be deemed to be amended accordingly; 

  
 ***Confidential Treatment
Requested*** 
 Page | 12 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(B)	 BioMedica hereby grants to Orchard, subject to the terms of this Agreement with respect to Collaboration
Particles and Collaboration Products a non-transferable, non-exclusive, worldwide, fully paid-up licence under the Manufacturing Know-How solely for the purposes of Manufacture of Collaboration Particles in the Field, provided that Orchard may grant sub-licences only in accordance with the following:

  

	 	(1)	 Orchard may not disclose the Manufacturing Know-How to any third party
nor grant any sub-licence to use the Manufacturing Know-How, including to any Orchard Affiliate, without the prior written consent of BioMedica, [***];

  

	 	(2)	 Orchard may not disclose the Manufacturing Know-How to any third party,
or Affiliate, or proposed sub-licensee, unless such third party, or Affiliate, or proposed sub-licensee has entered into a legally binding confidentiality agreement with
BioMedica and enforceable by BioMedica, on terms [***] to BioMedica; and 

  

	 	(3)	 in the event that Orchard discloses any Manufacturing Know-How to any
third party, including to any Orchard Affiliate, Orchard shall remain fully liable to BioMedica in respect of any acts or omissions of such third party that would, if effected by Orchard, constitute a breach of this Agreement. 

(“Collaboration Product Licence”) 
  

	 	(b)	 with respect to Other Particles and Other Products a licence under the BioMedica Background IPR, which licence
shall be: 

  

	 	(i)	 non-exclusive and worldwide; and 

 

	 	(ii)	 solely for the purposes of research, development, Commercialisation, and Manufacture of Other Particles and
Other Products in the Field; 

 (“Other Product Licence”) 

 

	 	(c)	 under the Orchard Arising IPR only: 

 

	 	(i)	 after the expiry of the royalty obligations under this Agreement, an exclusive, worldwide, royalty free,
perpetual, irrevocable, sublicensable licence, solely for the purposes of research, development, Commercialisation and Manufacture of Collaboration Particles and Collaboration Products in the Field; and 

 

	 	(ii)	 a non-exclusive, worldwide, royalty free, perpetual, irrevocable
sublicensable licence, for all purposes outside the Field. 

  

	3.2	 Particle Restrictions. Orchard and its Affiliates and sublicensees shall, with respect to all
Collaboration Particles and Other Particles: 

  
 ***Confidential Treatment
Requested*** 
 Page | 13 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(a)	 use the Collaboration Particles and Other Particles only for the generation of Collaboration Products or Other
Products respectively; and/or 

  

	 	(b)	 supply the Collaboration Particles and Other Particles only to Orchard or its Affiliates or Third Parties who
hold a sublicence in compliance with this Agreement, under the BioMedica Background IP, for the purposes of research, development and/or Commercialisation of the applicable Collaboration Products and/or Other Products in the Field.

  

	3.3	 Sublicensing Rights.  

 

	 	(a)	 Subject to clauses 3.3(c) and 3.3(d), Orchard may sublicense its rights under the Collaboration Product Licence
(including through multiple tiers) solely for the purposes set out in clause 3.1(a)(ii) subject to clause 3.1(a)(iii). 

  

	 	(b)	 Subject to clauses 3.3(c) and 3.3(d), Orchard may sublicense its rights under the Other Product Licence
(including through multiple tiers) solely for the purposes of research, development, Commercialisation, and Manufacture of Other Particles and Other Products in the Field. 

 

	 	(c)	 Orchard shall only disclose Confidential Information of BioMedica to a sublicensee under the Collaboration
Product Licence or Other Product Licence if such sublicensee has undertaken directly to BioMedica to comply with terms of confidentiality and non-use of such Confidential Information on terms at least as
stringent as those in this Agreement. 

  

	 	(d)	 All sublicences (including through multiple tiers) under the BioMedica Background IPR and/or Arising IPR must:

  

	 	(i)	 include legally binding provisions at least as stringent as those contained in clauses 3.2, 3.3(b), 3.3(c) and
3.3(d) and 8; and 

  

	 	(ii)	 such sublicences shall automatically terminate upon termination of this Agreement. 

 

	 	(e)	 Orchard shall remain fully liable to BioMedica in respect of any acts or omissions of any Affiliate,
sublicensee (through multiple tiers) or subcontractor of Orchard, its Affiliates or sublicensees (through multiple tiers), that would, if effected by Orchard, constitute a breach of this Agreement. 

 

	3.4	 Registration. If requested by Orchard, BioMedica shall (at Orchard’s expense, [***]) execute such
formal licences as may be necessary or appropriate for registration with patent offices and other relevant authorities. In the event of any conflict in meaning between any such licence and the provisions of this Agreement, the provisions of this
Agreement shall prevail. 

  

	3.5	 Regulatory. As soon as reasonably practicable after the Effective Date, but not later than [***], the
Parties shall enter into a Pharmacovigilance Agreement, setting forth the worldwide pharmacovigilance procedures for the Parties with respect to Collaboration Particles and Collaboration Products and which will include those terms set out in
Schedule 8. 

  
 ***Confidential Treatment
Requested*** 
 Page | 14 

			
	28.11.2016	  	CONFIDENTIAL

  

	4.	 Collaboration 

 

	4.1	 Collaboration. For the Collaboration Term: 

 

	 	(a)	 BioMedica shall use Commercially Reasonable Efforts to perform the activities set out in the Collaboration
Plan: 

  

	 	(i)	 in accordance with the provisions of this Agreement and, if applicable, the Quality Agreement between the
Parties relating to such activities; 

  

	 	(ii)	 in a professional manner, in conformance with that level of care and skill ordinarily exercised by other
professionals in the biopharmaceutical industry in similar circumstances; and 

  

	 	(iii)	 in accordance with the time-lines in the Collaboration Plan [***]; 

 

	 	(b)	 Orchard shall use Commercially Reasonable Efforts to: 

 

	 	(i)	 provide all documentation and materials (including Collaboration Materials) reasonably requested by BioMedica
as necessary for BioMedica to conduct its obligations under the Collaboration Plan; and 

  

	 	(ii)	 perform all activities set out in the Collaboration Plan as being the responsibility of Orchard, in all cases,
in accordance with the time-lines in the Collaboration Plan. 

  

	4.2	 Amendments to Collaboration Plan. Upon request by either Party, the Parties will negotiate in good faith
and seek to agree, through the Project Team and/or Steering Committee, amendments to the Collaboration Plan. In the event that any amendment to the Collaboration Plan would have the effect that any programme of work relevant to the achievement of
any Milestone is amended or deleted such that a Milestone can no longer reasonably be achieved pursuant to the amended Collaboration Plan, such amendments to the Collaboration Plan may only be made: 

 

	 	(a)	 [***]; and 

  

	 	(b)	 [***]. 

  

	4.3	 Subsequent Indications. Orchard may, at any time, request that an additional indication ([***]) be
included in this Agreement and the following provisions shall apply: 

  

	 	(a)	 Orchard may by written notice to BioMedica received on or before [***], nominate [***] and upon [***], such
indication shall become a Subsequent Indication; and/or 

  

	 	(b)	 Orchard may, at any time after [***], request [***] and, if [***], such additional indication shall become a
Subsequent Indication. 

  

	4.4	 Collaboration Materials. Each Party shall provide to the other Party the Collaboration Materials. [***].
The receiving Party with respect to the such Collaboration Materials shall use the Collaboration Materials: 

  

	 	(a)	 only for the purpose of performing the activities assigned to it under the Collaboration Plan, and not for any
other purpose; 

  
 ***Confidential Treatment
Requested*** 
 Page | 15 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(b)	 in compliance with this Agreement and the Quality Agreement, all Applicable Laws and all reasonable
instructions of the providing Party; and 

  

	 	(c)	 only in the facilities of such Party, collaborators or its approved subcontractors and under suitable
containment conditions; 

 Upon the later to occur of completion of the activities assigned to it under the Collaboration
Plan or, if earlier, termination of the collaboration or this Agreement, BioMedica shall either (i) destroy any Collaboration Materials received from Orchard in connection with the Collaboration Plan; or (ii) transfer such Collaboration
Materials to Orchard. Title in all such Collaboration Materials provided by Orchard shall remain with Orchard and Title to any Collaboration Materials transferred by BioMedica to Orchard shall pass to Orchard on delivery to Orchard. 

The Parties agree that the materials transferred between the Parties prior to the Effective Date pursuant to the Material Transfer Agreement
dated 1 March 2016 shall be deemed to be Collaboration Materials subject to the terms of this Agreement and the provisions of the Material Transfer Agreement shall no longer apply to such materials. 

 

	4.5	 Subcontracting. 

 

	 	(a)	 Orchard shall be entitled to subcontract its obligations under this Agreement subject to the provisions of this
clause 4.5 and the consent of BioMedica, [***] (provided that the other conditions of clause 4.5(c) are met). 

  

	 	(b)	 Other than as set forth in this clause, BioMedica shall not be entitled to subcontract its obligations under
the Collaboration Plan, in whole or in part, without the prior written consent of Orchard [***]. 

  

	 	(c)	 The relevant Party shall ensure that all subcontractors are bound by confidentiality obligations and by
provisions in relation to intellectual property which enable such Party to grant the rights set out in this Agreement. [***]. 

  

	 	(d)	 Notwithstanding the foregoing, BioMedica may subcontract its obligations under the Collaboration Plan to the
subcontractors or subcontactors listed in Schedule 2 or in the Collaboration Plan or in the Quality Agreement. 

  

	4.6	 Reports. BioMedica shall provide to Orchard, in advance of each regularly scheduled Steering Committee
meeting, a report detailing its activities under the Collaboration Plan, the results of such activities, and all Collaboration Costs incurred by it. 

  

	4.7	 Unforeseen Events. Each Party shall promptly inform the other about any unforeseen results,
problems, difficulties, delays, or the like with regard to the activities under the Collaboration Plan. [***]. The Steering Committee shall review any applicable timelines set forth in the Collaboration Plan and agree on commercially reasonable
revised timelines. 

  
 ***Confidential Treatment
Requested*** 
 Page | 16 

			
	28.11.2016	  	CONFIDENTIAL

  

	4.8	 Collaboration Costs. 

 

	 	(a)	 Orchard shall be liable for the Collaboration Costs for the activities as set out in the Collaboration Plan.

  

	 	(b)	 Within [***] days after the end of each Quarter, BioMedica shall provide Orchard with a statement of the
activities performed under the Collaboration Plan and the Collaboration Costs incurred by it in such Quarter (each, a “Collaboration Costs Report”) together with an invoice for such Collaboration Costs. Orchard shall pay such
invoice within [***] days after receipt of such invoice. 

  

	 	(c)	 If Orchard in good faith reasonably disputes an amount provided in such Collaboration Costs Report then such
disputed amount shall be reviewed by the Steering Committee, and upon resolution, any payment owed with respect to the then-undisputed amounts shall be paid in the next payment cycle as set forth above. 

 

	 	(d)	 If requested by Orchard, BioMedica shall promptly provide to Orchard any invoices or other supporting
documentation for any payments to a Third Party included in any Collaboration Costs. 

  

	4.9	 Milestone Deadlines. Notwithstanding the qualified nature of Orchard’s obligations under clause
4.1(b), the Parties acknowledge that any delay by Orchard in the provision of documentation and/or materials or performance of its activities set out in the Collaboration Plan (together the “Orchard Performance Obligations”) could
prevent BioMedica from achieving the Milestones on or before the dates for such achievement as set out in Schedule 3. In the event that there is a delay in the performance of any Orchard Performance Obligations caused by Orchard and such delay
directly or indirectly prevents BioMedica from achieving a Milestone on or before the dates for such achievement as set out in Schedule 3, the dates for achieving the affected Milestone and any linked subsequent Milestones which are affected by such
delay shall be extended by the length of such delay. In the event that the Parties are unable to agree on (i) whether the delay in the performance of any Orchard Performance Obligations caused the delay or directly or indirectly prevented
BioMedica from achieving a Milestone by the due date; or (ii) the applicable extension to such dates, the matter shall be referred to the Steering Committee for determination in accordance with clause 2.6. 

 

	5.	 Collaboration Intellectual Property 

 

	5.1	 Background IPR. Nothing in this Agreement will affect either Party’s ownership of any BioMedica
Background IPR or Orchard Background Patents. No licence to use any such rights is granted or implied except as expressly set out in this Agreement. 

  

	5.2	 Licence Grant for Collaboration Activities. Orchard hereby grants to BioMedica a non-exclusive non-transferable licence under the Orchard Background Patents and Orchard Arising IPR, solely for the purpose of and to the extent necessary to enable BioMedica
to perform the activities assigned to it under the Collaboration Plan and any Supply Agreement. BioMedica shall only be entitled to [***]. 

  
 ***Confidential Treatment
Requested*** 
 Page | 17 

			
	28.11.2016	  	CONFIDENTIAL

  

	5.3	 BioMedica Arising IPR. BioMedica shall solely own all BioMedica Arising IPR. Orchard hereby assigns, by
way of present and future assignment with full title guarantee, and shall procure that its Representatives assign, by way of present and future assignment with full title guarantee to BioMedica all right, title and interest in the BioMedica Arising
IPR. To the extent that any such BioMedica Arising IPR cannot be assigned by way of future assignment, Orchard agrees to assign with full title guarantee, and shall procure that its Representatives agree to assign with full title guarantee, to
BioMedica all right, title and interest in the BioMedica Arising IPR. At BioMedica’s written request and at [***], Orchard shall, and shall ensure that its Representatives shall, execute all documents and do all things requested by BioMedica to
vest and confirm in BioMedica all right, title, and interest in and to all BioMedica Arising IPR. BioMedica shall be responsible, at its discretion, in its sole name and at its sole cost for obtaining, prosecuting, and maintaining patents and patent
applications within or claiming any BioMedica Arising IPR. Orchard will fully cooperate with BioMedica, at BioMedica’s cost, in connection with the filing, prosecution and maintenance of any patents claiming any BioMedica Arising IPR, including
by providing access to relevant persons and executing all documentation reasonably requested by BioMedica. 

  

	6.	 Equity and Royalties 

 

	6.1	 Upfront Equity. In partial consideration of the rights and licences granted to Orchard hereunder,
Orchard shall, with effect from the Effective Date issue to BioMedica 735,000 ordinary shares of Orchard (representing 1.95% of the Equity), subject to signature by BioMedica of the Share Subscription Letter. 

 

	6.2	 Milestone Based Equity. In further consideration of the rights and licences granted to Orchard hereunder
Orchard shall issue to BioMedica the equity described in Schedule 3 upon achievement of the Milestones described in Schedule 3, subject to the provisions of clause 6.1(d) of the Supply Agreement. 

 

	6.3	 Collaboration Product Royalties. In further consideration of the rights and licences granted to Orchard
hereunder, in respect of all Collaboration Products generated using Collaboration Particles: 

  

	 	(a)	 where such Collaboration Product is sold or otherwise supplied on or before [***], a royalty on Net Sales of
such Collaboration Product of [***]%; 

  

	 	(b)	 where such Collaboration Product is sold or otherwise supplied after [***] and on or before [***], a royalty on
Net Sales of such Collaboration Product of [***]%; and 

  

	 	(c)	 where such Collaboration Product is sold or otherwise supplied after [***] and before 31 January 2039, a
royalty on Net Sales of such Collaboration Product of [***]%, 

 except in each case as set out in clause 6.5. 

 

	6.4	 Other Product Royalties. In further consideration of the rights and licences granted to Orchard
hereunder, in respect of all Other Products generated using Other Particles, where: 

  

	 	(a)	 the manufacture of such Other Particle, had it been manufactured in [***], would have been covered by, would
but for a licence to Orchard have infringed, one or more Valid Claims of a Platform Patent; and 

  
 ***Confidential Treatment
Requested*** 
 Page | 18 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(b)	 such Other Product is sold or otherwise supplied on or before [***]; 

a royalty on Net Sales equal to [***]% except as set out in clause 6.5. 

 

	6.5	 Royalties Payable for Products for Compassionate Use. In respect of any Collaboration Product or Other
Product which is provided on a compassionate use basis in any country at any time prior to obtaining marketing authorisation for such Collaboration Product or Other Product in such country, the royalties payable in respect of such Products shall be
[***] 6.3 and 6.4 until the first commercial sale post marketing authorisation for such Product is made in such country. 

  

	6.6	 Duration of Royalty Obligations. The Parties acknowledge and agree that Orchard’s obligations to
pay royalties on Net Sales of Products as set forth in this clause 6 have been agreed via arm’s length negotiations between sophisticated commercial entities to be a fair and reasonable consideration, payable in instalments over a
mutually-agreed period of time, in recognition of the rights granted to Orchard hereunder. 

  

	6.7	 Royalty Statements. Within [***], Orchard shall send to BioMedica a royalty statement (“Royalty
Statement”) setting out in respect of each of Orchard, its Affiliates and sublicensees: 

  

	 	(a)	 in respect of each country in which Products are sold: 

[***] 
  

	 	(b)	 the resulting amount payable by Orchard, in GBP. 

 

	6.8	 Royalty Invoices. Following receipt of the Royalty Statement, BioMedica shall issue an invoice to
Orchard for the royalty payable for the reported [***]. Orchard shall pay such invoice within [***] after receipt of such invoice. 

  

	6.9	 Sums Due to BioMedica. All sums due to BioMedica under this Agreement: 

 

	 	(a)	 subject to BioMedica issuing a valid VAT invoice, are exclusive of Value Added Tax, which where applicable will
be paid by Orchard in addition; 

  

	 	(b)	 shall be paid in: 

  

	 	(i)	 GBP in cash by transferring an amount in aggregate to the following account: 

 

			
	Account name:	  	[***]
	Account number:	  	[***]
	Sort code:	  	[***]
	IBAN:	  	[***]
	SWIFT:	  	[***]

  

	 	(c)	 when conversion of payments from any foreign currency is required Orchard shall convert such amounts into an
amount in GBP using its customary conversion procedures as used in in preparing its audited financial statements; 

  
 ***Confidential Treatment
Requested*** 
 Page | 19 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(d)	 shall be made subject to any applicable withholding taxes, in respect of which Orchard shall be entitled to
deduct from payments made to BioMedica under this Agreement the amount of any withholding taxes required to be withheld, to the extent paid to the appropriate governmental authority on behalf of BioMedica (and not refunded or reimbursed). Orchard
shall deliver to BioMedica, upon request, proof of payment of all such withholding taxes. Orchard shall provide reasonable assistance to BioMedica in seeking any benefits available to BioMedica with respect to government tax withholdings by any
relevant law, regulation or double tax treaty. 

  

	 	(e)	 shall be made by the due date; provided that any payment which falls due on a date which is not a
Business Day in the location from which the payment will be made may be made on the next Business Day in such location; and 

  

	 	(f)	 if any undisputed payment is not made within [***] days after the due date, BioMedica may charge interest on
any outstanding amount of such payment on a daily basis at a rate equivalent to [***] above the base rate of the Bank of England then in force in London. 

  

	7.	 Records and Audit 

 

	7.1	 Records. Orchard shall, and shall procure that its Affiliates and sublicensees shall, keep at its or
their normal place of business detailed and up-to-date records and accounts in accordance with their respective Accounting Standards as consistently applied of Net Sales
and any amounts due under this Agreement (as applicable), in each case for [***]. Such records shall be in sufficient detail to enable BioMedica to verify the matters to which they pertain. 

 

	7.2	 Audit Rights. 

 

	 	(a)	 BioMedica may, upon written notice to Orchard, appoint an internationally-recognised independent accounting
firm (which is reasonably acceptable to Orchard (the “Auditor”) for the purpose of verifying the accuracy of any statement or report given to BioMedica under this Agreement. Before beginning its audit, the Auditor shall execute an
undertaking acceptable to Orchard by which the Auditor shall keep confidential all information reviewed during such audit. [***]. 

  

	 	(b)	 Orchard and its Affiliates and sublicensees shall make their records available for inspection by such Auditor
during regular business hours at such place or places where such records are customarily kept, upon receipt of reasonable advance notice from BioMedica. The records shall be reviewed solely to verify the accuracy of any statement or report given to
BioMedica under this Agreement. [***]. In addition, BioMedica shall only be entitled to audit the relevant books and records of Orchard, its Affiliates and sublicensees for a period of [***] after receipt of the applicable report or statement.
BioMedica agrees to hold in strict confidence all information received and all information learned in the course of any audit or inspection, except to the extent necessary to enforce its rights under this Agreement or if disclosure is required by
law, regulation or judicial order. 

  

	 	(c)	 The Auditor shall provide its audit report and basis for any determination to Orchard at the time such report
is provided to BioMedica, before it is considered final. Orchard shall have the right to request a further determination by such Auditor as to matters which Orchard disputes within [***] following

  
 ***Confidential Treatment
Requested*** 
 Page | 20 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	
receipt of such report. Orchard will provide BioMedica and the Auditor with a reasonably detailed statement of the grounds upon which it disputes any findings in the audit report and the Auditor
shall undertake to complete such further determination within [***] after the dispute notice is provided, which determination shall be limited to the disputed matters. The Parties agree that they shall use reasonable efforts, through the
participation of finance representatives of both companies, to resolve any remaining dispute arising in relation to the Audit by good faith discussion. 

  

	 	(d)	 In the event that the final result of the inspection reveals an undisputed underpayment or overpayment by
either Party, the underpaid or overpaid amount shall be settled promptly [***]. 

  

	 	(e)	 BioMedica shall be responsible for the Auditor’s charges unless the Auditor certifies that there is an
overcharge, or under-reporting and underpayment, of more than [***] in aggregate amounts payable for any Year, in which case Orchard shall pay the Auditor’s charges in respect of that inspection. 

 

	8.	 Confidential Information 

 

	8.1	 Duty of Confidence. Each Receiving Party shall: 

 

	 	(a)	 keep the Confidential Information of the Disclosing Party secret and confidential at all times;

  

	 	(b)	 not disclose or permit the disclosure of any Confidential Information of the Disclosing Party, in whole, in
part, or in summary, to any Person, except as expressly permitted by this Agreement and/or the Supply Agreement; 

  

	 	(c)	 not use the Confidential Information of the Disclosing Party or permit it to be used, in whole or in part, for
any purpose other than performance of the obligations and enjoyment of the rights granted under this Agreement and/or the Supply Agreement; and 

  

	 	(d)	 inform the Disclosing Party immediately if it becomes aware of the possession, use or knowledge of any of the
Confidential Information of the Disclosing Party by an unauthorised person, and to provide any assistance in relation to such unauthorised possession, use or knowledge that the Disclosing Party may require. 

 

	8.2	 Representatives. The Receiving Party shall permit access to the Confidential Information of the
Disclosing Party only to those of its Representatives who: 

  

	 	(a)	 reasonably require such access for the performance of the obligations and/or enjoyment of the rights granted
under this Agreement and/or the Supply Agreement; 

  

	 	(b)	 have been informed of the confidential nature of such Confidential Information, the Disclosing Party’s
interest in such Confidential Information, and the provisions of this Agreement; and 

  
 ***Confidential Treatment
Requested*** 
 Page | 21 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(c)	 have entered into legally binding confidentiality obligations to the Receiving Party on terms that are no less
onerous than those set out in this Agreement, and which extend to such Confidential Information. 

 The Receiving Party
shall ensure that all those Representatives who have access to the Confidential Information of the Disclosing Party comply with the provisions of this Agreement. Notwithstanding any other provision of this Agreement, the Receiving Party shall be
liable to the Disclosing Party for any acts or omissions of any such Representative, that would, if effected by the Receiving Party, constitute a breach of this Agreement. 
  

	8.3	 Exceptions. The Receiving Party’s obligations under clause 8.1 shall not apply to any Confidential
Information of the Disclosing Party that the Receiving Party can prove by means of reasonable written evidence: 

  

	 	(a)	 was known to the Receiving Party prior to disclosure by the Disclosing Party; 

 

	 	(b)	 is or becomes publicly known other than as a result of breach of this Agreement by the Receiving Party or by
anyone to whom the Receiving Party disclosed the Confidential Information of the Disclosing Party; 

  

	 	(c)	 is received by the Receiving Party from a Third Party lawfully entitled to make the disclosure without
restrictions on such Third Party’s rights to disclose or use; or 

  

	 	(d)	 is developed by or on behalf of the Receiving Party without any direct or indirect access to, or use or
knowledge of, the Confidential Information of the Disclosing Party (except that this exception does not extend to the Arising IPR); 

except that the above exceptions do not extend to circumstances where the Confidential Information is specific, does not fall within the above
exceptions, and is embraced by more general information which does fall within the above exceptions. 
  

	8.4	 Required Disclosures. The Receiving Party will not be in breach of its obligations under this Agreement
to the extent that it is required to disclose Confidential Information of the Disclosing Party by law (provided, in the case of a disclosure under any freedom of information legislation, that the exemptions under that legislation do not apply) or
order of a court or other public body or regulatory authority or Competent Authority that has jurisdiction over it or pursuant to the rules of any recognized stock exchange, provided that, before making such a disclosure, the Receiving Party shall,
to the extent it is legally permitted to do so: 

  

	 	(a)	 inform the Disclosing Party of the proposed disclosure as soon as possible, and if possible before the court or
other public body orders the disclosure; 

  

	 	(b)	 take into account reasonable requests of the Disclosing Party in relation to such disclosure;

  

	 	(c)	 ask the court or other public body to treat such Confidential Information as confidential; and

  

	 	(d)	 permit and assist the Disclosing Party to make representations to the court or other public body in respect of
the disclosure and/or confidential treatment of such Confidential Information. 

  
 ***Confidential Treatment
Requested*** 
 Page | 22 

			
	28.11.2016	  	CONFIDENTIAL

  

	8.5	 Additional Disclosures. In addition to disclosures allowed under clause 8.4: 

 

	 	(a)	 Orchard may disclose Confidential Information of BioMedica to the extent such disclosure is necessary in
connection with exercising or sublicensing (or potential sublicensing) the rights granted under this Agreement, provided that: 

  

	 	(i)	 the provisions of clauses 3.1(a)(iii)(B), 3.3(c) and 4.5(c) are have been complied with where applicable; and

  

	 	(ii)	 in all other events, such disclosure is made only under obligations of confidence and non-use at least as stringent as set out in this Agreement. 

  

	 	(b)	 BioMedica may disclose Orchard Arising IP to the extent such disclosure is necessary in connection with:

  

	 	(i)	 obtaining patent protection with respect to such Orchard Arising IPR; 

 

	 	(ii)	 [***]; 

  

	 	(c)	 BioMedica may disclose, to any licensor or assignor of Intellectual Property Rights to BioMedica, financial
Confidential Information of Orchard provided to BioMedica under this Agreement to the extent required and for the specific purpose of enabling BioMedica to comply with its contractual royalty reporting obligations to any such licensor or assignor of
Intellectual Property Rights to BioMedica; provided that any such disclosure is made only under obligations of confidence and non-use at least as stringent as set out in this Agreement. 

 

	 	(d)	 Each Party and its Affiliates may disclose the existence of this Agreement to financial or institutional
potential and actual investors or potential purchasers of the business of such Party or its Affiliates in connection with: 

  

	 	(i)	 the raising of finance; 

 

	 	(ii)	 the sale of any equity interest in such Party or its Affiliates: or 

 

	 	(iii)	 the sale of the business or relevant part of the business of the Party or its Affiliates.

  

	8.6	 Return and Destruction of Confidential Information. At the Disclosing Party’s written request and
on expiration or termination of this Agreement, the Receiving Party shall: 

  

	 	(a)	 promptly destroy or erase all Confidential Information of the Disclosing Party that the Receiving Party has
received under this Agreement including any copies made and delete all electronic copies of any such Confidential Information from the Receiving Party’s computer systems, but excluding documents related to the GMP manufacture, release,
distribution, etc. which must be retained for regulatory purposes; and 

  

	 	(b)	 make no further use of any such Confidential Information. 

  
 ***Confidential Treatment
Requested*** 
 Page | 23 

			
	28.11.2016	  	CONFIDENTIAL

  

 The Receiving Party may, however, keep one copy of the Confidential Information of the
Disclosing Party in its legal advisor’s files solely for the purpose of enabling it to comply with the provisions of this Agreement and as required to comply with the requirements of relevant regulatory authorities, and the Receiving Party
shall not be required to remove such Confidential Information of the Disclosing Party from its back-up or archive electronic records. 
  

	8.7	 Press Releases and Publicity. Neither Party shall make, nor permit any Person to make, any public
announcement, whether oral or written, concerning this Agreement or the Supply Agreement or make any use of the name, symbol, trade mark, trade name or logo of the other Party or its Affiliates without the prior written consent of the other Party
(such consent not to be unreasonably withheld or delayed); provided, however, that notwithstanding any other provision of this Agreement each Party shall be permitted to make an announcement in the agreed form appended to this Agreement as Schedule
4 and otherwise repeat the information contained therein as required by law or any other governmental regulation and such activities shall not constitute a breach of this Agreement. 

 

	9.	 Warranties and Liability 

 

	9.1	 Mutual Representations and Warranties. Each Party warrants to the other as of the Effective Date that:

  

	 	(a)	 it is a corporation duly organised, validly existing, and in good standing under the laws of its jurisdiction
of formation; 

  

	 	(b)	 it has full corporate power and authority to execute, deliver, and perform this Agreement, and has taken all
corporate action required by law and its organisational documents to authorise the execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement; 

 

	 	(c)	 this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms;

  

	 	(d)	 all consents, approvals and authorisations from all governmental authorities or other Third Parties required to
be obtained by such Party in connection with this Agreement have been obtained; and 

  

	 	(e)	 the execution and delivery of this Agreement and all other instruments and documents required to be executed
pursuant to this Agreement do not and shall not (i) conflict with or result in a breach of any provision of its organisational documents, (ii) result in a breach of any agreement to which it is a party; or (iii) violate any law; and

  

	9.2	 BioMedica Warranties. BioMedica represents and warrants that: 

 

	 	(a)	 so far as it is aware as of the Effective Date there are no claims, challenges, oppositions, nullity actions,
interferences, inter-partes reexaminations, inter-partes reviews, post-grant reviews, derivation proceedings, or other proceedings pending in respect of the BioMedica Patents (other than matters raised in the ordinary course of patent prosecution);

  

	 	(b)	 so far as it is aware as of the Effective Date and without having made any particular enquiry [***];

  
 ***Confidential Treatment
Requested*** 
 Page | 24 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(c)	 so far as it is aware BioMedica has filed and prosecuted patent applications within the BioMedica Patents in
good faith and complied with all duties of disclosure with respect thereto; 

  

	 	(d)	 so far as it is aware BioMedica has not committed any act, or omitted to commit any act, that may cause the
BioMedica Patents to expire prematurely or be declared invalid or unenforceable; 

  

	 	(e)	 all application, registration, maintenance and renewal fees in respect of the BioMedica Patents as of the
Effective Date have been paid and all necessary documents and certificates have been filed with the relevant agencies for the purpose of maintaining the BioMedica Patents; and 

 

	 	(f)	 as at the Effective Date, so far as BioMedica is aware, BioMedica is not in breach of the [***];

  

	 	(g)	 BioMedica has not granted any Third Party rights that would otherwise interfere or be inconsistent with
Orchard’s rights hereunder. 

  

	9.3	 Orchard Warranties. Orchard represents and warrants that: 

 

	 	(a)	 Orchard has the right to grant to BioMedica the right to use the sequences, information and/or Collaboration
Materials which are provided by or on behalf of Orchard to BioMedica in connection with this Agreement; and 

  

	 	(b)	 so far as Orchard is aware as of the Effective Date and without having made any particular enquiry, the use by
Orchard and BioMedica of the sequences, information and/or Collaboration Materials which are provided by or on behalf of Orchard to BioMedica in connection with this Agreement will not give rise to any infringement nor misappropriation of the
Intellectual Property Rights of any Third Party. 

  

	9.4	 No Other Warranties. Each of the Parties acknowledges that, in entering into this Agreement, it does not
do so in reliance on any representation, warranty, or other provision except as expressly provided in this Agreement, and any conditions, warranties or other terms implied by statute or common law are excluded from this Agreement to the fullest
extent permitted by law. 

  

	10.	 Duration and Termination 

 

	10.1	 Term. This Agreement shall commence on the Effective Date and, shall expire when no further payments are
due to BioMedica under this Agreement unless earlier terminated by the Parties by agreement in writing. On expiry of this Agreement upon expiry of all payment obligations, all of the licences granted by BioMedica in this Agreement shall become fully
paid up, royalty free, perpetual and irrevocable. 

  

	10.2	 Termination of Collaboration. 

 

	 	(a)	 Orchard may terminate the performance of the Collaboration Plan by giving to BioMedica written notice at [***]
in advance of such termination; 

  
 ***Confidential Treatment
Requested*** 
 Page | 25 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(b)	 If either Party is in material breach of any material obligation hereunder (including failure by Orchard to
make an undisputed payment due under this Agreement) with respect to the performance of the Collaboration Plan, the non-breaching Party may give written notice to the breaching Party specifying the claimed
particulars of such breach, and in the event such material breach is not cured within [***] after such notice [***], the non-breaching Party shall have the right thereafter to terminate the performance of the
Collaboration Plan immediately by giving written notice to the breaching Party to such effect; provided, however, that if such breach is capable of being cured but cannot be cured within such cure period and the breaching Party initiates actions to
cure such breach within such period and thereafter diligently pursues such actions, the breaching Party shall have such additional period as is reasonable in the circumstances to cure such breach; 

 

	 	(c)	 In the event of termination of the performance of the Collaboration Plan: 

 

	 	(i)	 by Orchard pursuant to Clause 10.2(a) or by BioMedica pursuant to Clause 10.2(b): 

 

	 	(A)	 Orchard shall, within [***] after the effective date of termination, pay to BioMedica: 

 

	 	(1)	 all expenses actually incurred by BioMedica in connection with the performance of the Collaboration Plan prior
to such effective date of termination; and 

  

	 	(2)	 all costs and expenses which BioMedica is committed to incur in connection with the performance of the
Collaboration Plan as at the effective date of termination and which could not be cancelled by BioMedica prior to expiry of such [***] period and which are actually incurred by BioMedica; and 

 

	 	(B)	 if the termination is by BioMedica pursuant to clause 10.2(b), [***]; and 

 

	 	(C)	 if the termination is by Orchard pursuant to clause 10.2(a) Orchard shall, within [***] after the effective
date of termination, [***]. 

  

	 	(ii)	 by Orchard pursuant to clause 10.2(b), Orchard shall within [***] after the effective date of termination, pay
to BioMedica: 

  

	 	(A)	 all expenses actually incurred by BioMedica in connection with the proper performance of the Collaboration Plan
in accordance with this Agreement prior to such effective date of termination; and 

  

	 	(B)	 all costs and expenses which BioMedica is committed to incur in connection with the performance of the
Collaboration Plan as at the effective date of termination and which could not be cancelled by BioMedica prior to expiry of such [***] period or which [***]. 

  

	10.3	 Termination of Agreement for Breach or Insolvency. 

  
 ***Confidential Treatment
Requested*** 
 Page | 26 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(a)	 If either Party is in material breach of any material obligation hereunder (including failure by Orchard to
make an undisputed payment due under this Agreement), the non-breaching Party may give written notice to the breaching Party specifying the claimed particulars of such breach, and in the event such material
breach is not cured within [***] after such notice [***], the non-breaching Party shall have the right thereafter to terminate this Agreement immediately by giving written notice to the breaching Party to such
effect; provided, however, that if such breach is capable of being cured but cannot be cured within such cure period and the breaching Party initiates actions to cure such breach within such period and thereafter diligently pursues such actions, the
breaching Party shall have such additional period as is reasonable in the circumstances to cure such breach. 

  

	 	(b)	 Either Party may terminate this Agreement without notice if an Insolvency Event occurs in relation to the other
Party. In any event when a Party first becomes aware of the likely occurrence of any Insolvency Event in regard to that Party, it shall promptly so notify the other Party in sufficient time to give the other Party sufficient notice to protect its
interests under this Agreement. 

  

	10.4	 Termination Not Sole Remedy. A Party’s right of termination under this Agreement, and the exercise
of any such right, shall be without prejudice to any other right or remedy (including any right to claim damages) that such Party may have in the event of a breach of contract or other default by the other Party. 

 

	10.5	 Effects of Termination by BioMedica. Upon termination of this Agreement by BioMedica pursuant to
clause 10.3: 

  

	 	(a)	 such termination shall be deemed to be a termination of the performance of the Collaboration Plan by BioMedica
pursuant to clause 10.2(b) and the provisions of clause 10.2(c)(i) shall apply; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]; 

  

	 	(d)	 subject to paragraph 10.5(c), Orchard shall no longer be licensed to use or otherwise exploit in any way under
this Agreement, either directly or indirectly, the BioMedica Background IPR or BioMedica Arising IPR; 

  

	 	(e)	 Orchard shall consent to the cancellation of any formal licence granted to it, or of any registration of it in
any register, in relation to any patents rights; and 

  

	 	(f)	 the Supply Agreement shall automatically terminate, subject to the survival and other consequences of
termination in such Supply Agreement. 

  

	10.6	 Effects of Termination by Orchard. Upon termination of this Agreement by Orchard pursuant to
clause 10.3: 

  

	 	(a)	 such termination shall be deemed to be a termination of the performance of the Collaboration Plan by Orchard
pursuant to clause 10.2(b) and the provisions of clause 10.2(c)(ii) shall apply; 

  

	 	(b)	 BioMedica shall have no further obligations under clauses 2 or 4 of this Agreement and Orchard shall not be
obliged to [***]; 

  
 ***Confidential Treatment
Requested*** 
 Page | 27 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(c)	 any Collaboration Particles or other materials that the Collaboration Plan contemplates [***];

  

	 	(d)	 the licence granted to Orchard under clause 3.1(c) and any licence described in this Agreement as being
irrevocable [***]; 

  

	 	(e)	 only in the event of a Fundamental Breach by BioMedica, the licences granted by BioMedica to Orchard under this
Agreement shall continue subject to all terms of this Agreement provided that: 

  

	 	(i)	 Orchard shall pay the royalties to BioMedica referred to in clauses 6.3 and 6.4 at [***] of the rates set out
in clauses 6.3 and 6.4; and 

  

	 	(ii)	 BioMedica shall otherwise retain all rights granted to it under this Agreement including the right to terminate
the rights which Orchard continues to hold under this Agreement in accordance with clause 10.3 as if this Agreement were still in effect; and 

  

	 	(f)	 Orchard shall consent to the cancellation of any formal licence granted to it, or of any registration of it in
any register, in relation to any patents rights to the extent that such licences no longer remain in effect. 

  

	 	(g)	 [***]. 

  

	10.7	 Survival. Clauses 1, 3.1(c), 3.2, 4.4, 5, 6.9, 7, 9, 10.4, 10.5, 10.6 (along with any clauses stated
therein as surviving termination where applicable), 10.7, 11, and 12 will continue in force indefinitely. Clause 8 will survive and continue in force for a period of [***] following expiry or termination of this Agreement. 

 

	11.	 Liability and Indemnities 

 

	11.1	 No Exclusion. Nothing in this Agreement shall exclude or limit, or purport to exclude or limit, a
Party’s liability in the case of: 

  

	 	(a)	 breach of clause 8; 

  

	 	(b)	 fraud or fraudulent misrepresentation; 

 

	 	(c)	 death or personal injury resulting from its negligence; or 

 

	 	(d)	 any other matter in respect of which it would be unlawful to exclude or restrict liability.

  

	11.2	 Limitation of Damages. Subject to clause 11.1 above: 

 

	 	(a)	 neither Party nor any of its Affiliates shall be liable in contract, tort, negligence, breach of statutory duty
or otherwise to the other Party for any consequential or indirect loss or damage (including lost profits, business or goodwill) arising out of this Agreement, except to the extent any such losses or damages (including lost profits, business or
goodwill) are required to be paid as part of a claim for which a Party provides indemnification under this clause 11; 

  

	11.3	 Orchard Indemnification. Orchard shall indemnify BioMedica and its Affiliates, and their respective
officers, directors, employees, contractors and agents (the “BioMedica Indemnitees”), from and against any and all Claims against a BioMedica Indemnitee arising out of: 

  
 ***Confidential Treatment
Requested*** 
 Page | 28 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(a)	 the research, development, use, Manufacture, or Commercialisation of any Collaboration Product or Other Product
by Orchard or its Affiliates or its or their sublicensees or subcontractors, including, but not limited to, any actual or alleged injury or death, claimed to result directly or indirectly from the possession, use or consumption of, or treatment
with, any such Product; or 

  

	 	(b)	 use by the BioMedica Indemnitees of Collaboration Materials or information provided to BioMedica by or on
behalf of Orchard, including, without limitation, infringement by the BioMedica Indemnitees of Third Party Intellectual Property Rights relating to the [***] by or on behalf of Orchard; or 

 

	 	(c)	 alleged infringement of any Third Party Intellectual Property Right relating specifically to Collaboration
Product or Other Product provided that (i) subject to paragraph (ii) below, this indemnity shall not apply in relation to any alleged infringement of any Third Party Intellectual Property Right which relates specifically to the process of
manufacture of any Collaboration Particle or Other Particle; and (ii) this indemnity shall apply in relation to alleged infringement of any Third Party Intellectual Property Right which relates to any of the sequences to be delivered to target
cells by any Collaboration Particle or Other Particle; 

 in each case, except to the extent that such Claim is
attributable to the negligence of, wilful misconduct of, or breach of this Agreement or the Supply Agreement by the BioMedica Indemnitees. 
  

	11.4	 BioMedica Indemnification. BioMedica shall indemnify Orchard and its Affiliates, and their respective
officers, directors, employees, contractors and agents (the “Orchard Indemnitees”), from and against any and all Claims against an Orchard Indemnitee arising out of the negligence or wilful misconduct of BioMedica or any of its
Affiliates or subcontractors except to the extent that such Claim is attributable to the negligence, wilful misconduct, or breach of this Agreement by the Orchard Indemnitees or sublicensees of Orchard. 

 

	11.5	 Indemnification Procedure. Where a Party (the “Indemnified Party”) seeks
indemnification from the other Party (the “Indemnifying Party”) under clause 11: 

  

	 	(a)	 the Indemnified Party shall provide prompt written notice to the Indemnifying Party of the assertion or
commencement of any Third Party claim, demand, action or suit; 

  

	 	(b)	 the Indemnifying Party shall have the right to assume (with its own counsel and at its own costs) the defence
and/or settlement of the same and shall not be liable for any settlement made by the Indemnified Party without the Indemnifying Party’s consent; 

  

	 	(c)	 the Indemnified Party shall: 

 

	 	(i)	 promptly provide all assistance and information reasonably required by the Indemnifying Party;

  
 ***Confidential Treatment
Requested*** 
 Page | 29 

			
	28.11.2016	  	CONFIDENTIAL

  

	 	(ii)	 not make any admission of liability, conclude any agreement or make any compromise with any person in relation
to such claim, demand, action or suit without the prior written consent of the Indemnifying Party (which consent shall not be withheld unreasonably); and 

  

	 	(iii)	 have the right to participate in (but not control) the defence of the claim, demand, action or suit and to
retain its own counsel in connection with such claim, demand, action or suit at its own expense. 

  

	11.6	 Mitigation of Loss. Each Indemnified Party will take and will ensure that its Affiliates take all such
reasonable steps and action as are necessary or as the Indemnifying Party may reasonably require in order to mitigate any Claims (or potential losses or damages) under this clause 11. Nothing in this Agreement shall or shall be deemed to relieve any
Party of any common law or other duty to mitigate any losses incurred by it. 

  

	12.	 General 

  

	12.1	 Force Majeure. Neither Party shall have any liability or be deemed to be in breach of this
Agreement for any delays or failures in performance of this Agreement that result from circumstances beyond the reasonable control of that Party and which circumstances are not reasonably foreseeable. The Party affected by such circumstances shall
promptly notify the other Party in writing when such circumstances cause a delay or failure in performance and use its reasonable endeavours to avoid or remove the causes of non-performance and shall continue
performance as expeditiously as possible as soon as such causes have been removed. If any circumstances described in this clause 12.1 prevent a Party from performing its material obligations under this Agreement for [***], the other Party may
terminate this Agreement by giving [***] written notice to the affected Party. 

  

	12.2	 Compliance with Law. Each Party shall perform its obligations under this Agreement in accordance with
all Applicable Laws are being performed. No Party shall, or shall be required to, undertake any activity under or in connection with this Agreement which violates, or which it reasonably believes, in good faith, may violate, any Applicable Law.

  

	12.3	 Further Action. Each Party agrees, without the necessity of any further consideration, to
execute, acknowledge, and deliver such further instruments, and do all further similar acts, as may be necessary or appropriate to carry out the purposes and intent of this Agreement. 

 

	12.4	 Notices and Other Communications. Any notice to be given under this Agreement must be in writing,
and be delivered to the other Party by courier or other recorded delivery post and will be deemed to be received on the date of delivery. Until changed by notice given in accordance with this clause 12.4, all notices should be addressed as follows:

  

			
	For BioMedica:	  	For Orchard:
		
	For the attention of: Company Secretary	  	For the attention of: [***]
		
	 Address: Oxford BioMedica (UK) Limited
  

Windrush Court, Transport Way, Oxford, OX4 6LT, United Kingdom
  

With a copy to: [***]
	  	 Address: Cheapside 5, EC2V 6AA
  

London (UK)

  
 ***Confidential Treatment
Requested*** 
 Page | 30 

			
	28.11.2016	  	CONFIDENTIAL

  

	12.5	 Amendment. This Agreement may only be amended in writing signed by duly authorised representatives of
the Parties. 

  

	12.6	 Assignment. Subject to the performance of the obligations and exercise of the rights described
directly or indirectly in clause 12.7, neither Party may assign, mortgage, charge or otherwise transfer any of its rights nor obligations under this Agreement without the other Party’s prior written consent (which consent shall not be
unreasonably withheld, delayed or conditioned), except that either Party may assign its rights and obligations under this Agreement, without the consent of the other to any Person acquiring all or substantially all of the assigning Party’s
assets or business to which this Agreement relates, provided that, in all cases: 

  

	 	(a)	 the assigning Party shall provide the other Party with prompt written notice of any such assignment; and

  

	 	(b)	 the permitted assignee shall assume the obligations of the assigning Party hereunder in writing.

  

	12.7	 Term Loan Agreement.  

 

	 	(a)	 The Parties agree and acknowledge: 

 

	 	(i)	 [***]; 

  

	 	(ii)	 [***]; and 

  

	 	(iii)	 [***]. 

  

	 	(b)	 [***]: 

  

	 	(i)	 [***]; 

  

	 	(ii)	 [***]; and 

  

	 	(iii)	 [***]. 

  

	12.8	 Third Party Rights. The provisions of this Agreement are for the sole benefit of the Parties and their
successors and permitted assigns, and they shall not be construed as conferring any rights to any Third Party except as otherwise expressly provided in clause 11 above. Except as expressly provided in clause 11 above, no person who is not a Party to
this Agreement, nor any employee, officer, agent, representative or subcontractor of either Party, nor any Affiliate of Orchard, shall have the right to enforce any term of this Agreement which expressly or by implication confers a benefit on that
person without the express prior agreement in writing of the Parties. 

  
 ***Confidential Treatment
Requested*** 
 Page | 31 

			
	28.11.2016	  	CONFIDENTIAL

  

	12.9	 Entire Agreement. This Agreement, together with the Share Subscription Letter, the Supply
Agreement, the Quality Agreement and all other agreements referred to in such documents constitute the entire agreement between the Parties relating to their subject matter and in relation to such subject matter supersedes all earlier understandings
and agreements between the Parties. In the event of any conflict between the terms of this Agreement and the Share Subscription Letter or the Supply Agreement, this Agreement shall prevail solely to the extent necessary to resolve such conflict.

  

	12.10	 Relationship. Nothing in this Agreement creates, implies or evidences any contract of employment or any
partnership or joint venture between the Parties, or authorises either Party to act as agent for the other. Moreover, each Party agrees not to construe this Agreement, or any of the transactions contemplated hereby, as a partnership for any tax
purposes. Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give any Party the power or authority to act for, bind, or commit the other. 

 

	12.11	 Waiver of Rights. No failure or delay by a Party to exercise any right or remedy provided under
this Agreement or by law or to insist upon compliance with any term or condition of this Agreement will constitute a waiver of that (or any other) right or remedy or excuse a similar subsequent failure to perform any such term or condition by the
other Party. No waiver shall be effective unless it has been given in writing and signed by the Party giving such waiver. No single or partial exercise of such right or remedy will preclude or restrict the further exercise of that (or any other)
right or remedy. 

  

	12.12	 Unenforceable Provisions. If the whole or any part of any provision of this Agreement is
unenforceable in any jurisdiction, then this Agreement shall be construed as if such provision were not contained herein and the remainder of this Agreement shall continue in full force and effect. The Parties will use their commercially reasonable
efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible to the original intent of the Parties. The validity and enforceability of that provision in any other
jurisdiction will not be affected. 

  

	12.13	 Counterparts. This Agreement may be executed in any number of counterparts, each of which is an
original but all of which together will constitute one document. 

  

	12.14	 Governing Law. This Agreement and any dispute arising out of or relating to this Agreement is governed
by and construed in accordance with English Law. 

  

	12.15	 Dispute Resolution; Jurisdiction and Venue. Any dispute arising out of or relating to this Agreement
shall be subject to the exclusive jurisdiction of the courts located in London, England and the Parties hereby consent to the personal jurisdiction of the courts of England. Nothing in this Agreement shall prevent either Party from seeking interim
relief in any court of competent jurisdiction. 

  

	12.16	 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall
be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. 

  

	12.17	 Expenses. Except as otherwise expressly provided in this Agreement, each Party shall pay the fees and
expenses of its respective lawyers and other experts and all other expenses and costs incurred by such Party incidental to the negotiation, preparation, execution and delivery of this Agreement. 

AGREED by the Parties to this Agreement through their authorised signatories: 

[SIGNATURES FOLLOW ON NEXT PAGE] 

  
 ***Confidential Treatment
Requested*** 
 Page | 32 

			
	28.11.2016	  	CONFIDENTIAL

  

			
	For and on behalf of	  	For and on behalf of
		
	OXFORD BIOMEDICA (UK) LIMITED:	  	ORCHARD THERAPEUTICS LIMITED:
		
	Signature	  	Signature
	/s/ Timothy Watts	  	/s/ Nicolas Koebel
		
	 Print name
 Timothy Watts
	  	 Print name
 Nicolas Koebel

		
	 Job title
 CFO
	  	 Job title
 SVP Business
Operatoins

		
	 Date
 28 November 2016
	  	 Date
 28.11.2016

  
 ***Confidential Treatment
Requested*** 
 Page | 33 

			
	28.11.2016	  	CONFIDENTIAL

  

 SCHEDULE 1: BIOMEDICA BACKGROUND IPR 

9Nov2016 (KH) 
  

							
	 Country
	  	 Patent Application No.
	  	 Patent Number
	  	 Expiry

	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]

  
 ***Confidential Treatment
Requested*** 
 Page | 34 

			
	28.11.2016	  	CONFIDENTIAL

  

							
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]

 KNOW-HOW 

Extensive know-how including, without limitation: 

[***] 

  
 ***Confidential Treatment
Requested*** 
 Page | 35 

			
	28.11.2016	  	CONFIDENTIAL

  

 SCHEDULE 2: APPROVED SUBCONTRACTORS 

 

			
	 Name
	  	 Service

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  
 ***Confidential Treatment
Requested*** 
 Page | 36 

			
	28.11.2016	  	CONFIDENTIAL

  

 SCHEDULE 3: MILESTONES 

Milestone 1 
 Orchard shall issue to BioMedica
188,462 ordinary shares in Orchard (representing [***]% of the Equity) upon the achievement, as determined by the Steering Committee pursuant to clause 2.6, of both: 
  

	1.	 [***]; and 

  

	2.	 [***]. 

Milestone 2 
 Orchard shall issue to BioMedica
[***] ordinary shares in Orchard (representing [***]% of the Equity) upon the achievement, as determined by the Steering Committee pursuant to clause 2.6, [***]. 

Milestone 3 
 Orchard shall issue to BioMedica
169,615 ordinary shares in Orchard (representing [***]%% of the Equity) upon the achievement, as determined by the Steering Committee pursuant to clause 2.6, [***]. 

[***]. 
 Milestone 4 

Orchard shall issue to BioMedica [***] ordinary shares in Orchard (representing [***]% of the Equity) upon the achievement, as determined by the Steering
Committee pursuant to clause 2.6, [***]. 

  
 ***Confidential Treatment
Requested*** 
 Page | 37 

			
	28.11.2016	  	CONFIDENTIAL

  

 SCHEDULE 4: AGREED FORM PRESS RELEASE 

Oxford BioMedica Announces a Strategic Alliance with Orchard Therapeutics 

Oxford, UK & London, UK– 29 November 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the
Group”) (LSE: OXB), a leading gene and cell therapy group, today announces it has entered into a strategic alliance with Orchard Therapeutics (“Orchard”), a biotechnology company dedicated to bringing transformative ex-vivo stem cell based gene therapies to patients with serious and life-threatening orphan diseases. 
 As part of
the agreement the Group will develop and supply lentiviral vectors used by Orchard for the manufacture of ex-vivo gene therapy products in primary immune deficiency disorders and inherited metabolic
disorders, including adenosine deaminase severe combined immunodeficiency (ADA-SCID), Mucopolysaccharidosis-IIIA (MPS-IIIA or Sanfilippo Syndrome type A) and undisclosed
follow-on indications. Orchard will lead the global clinical development and commercialisation of collaboration programs in Europe, the United States and in other regions. 

Under the terms of the collaboration and licence agreement, Oxford BioMedica will receive a 1.95% equity stake in Orchard and will be entitled to royalties on
future sales of products covered by the collaboration. The Group will provide process development services and manufacture clinical and commercial GMP-grade lentiviral vectors for Orchard. The process
development arrangements include performance-related incentives through which Oxford BioMedica could receive a further 1.95% equity stake in Orchard. The Group has also granted an exclusive intellectual property licence to Orchard for collaboration
programmes. 
 John Dawson, Chief Executive Officer of Oxford BioMedica, commented: “We are delighted to initiate a Strategic Alliance with
Orchard Therapeutics and look forward to working with them to develop and launch much needed treatments for patients in desperate need of better treatment options. The alliance combines Oxford BioMedica’s world-leading capabilities in
lentiviral vector process development and bioprocessing expertise with Orchard’s expertise in the development and commercialisation of gene therapies for orphan diseases. This further demonstrates Oxford BioMedica’s position as a “go
to” partner for companies and academic institutions working with lentiviral vector based products.”  
 Stewart Craig, Chief
Manufacturing Officer of Orchard Therapeutics Ltd., commented: “Orchard is a leader in bringing transformative gene therapies to patients with serious and life threatening orphan diseases. This alliance with Oxford BioMedica
represents a key element of the supply chain for manufacture of our ex vivo gene-modified stem cell products. We expect that Oxford BioMedica’s expertise in the development and manufacture of lentiviral vectors, along with their proven
experience of working with global pharma companies will accelerate our ability to potentially address a series of devastating genetic diseases. We are excited about the potential for this alliance to deliver real patient benefits.” 

  
 ***Confidential Treatment
Requested*** 
 Page | 38 

			
	28.11.2016	  	CONFIDENTIAL

  

 -Ends- 
  

			
	 For further information, please contact:
  
	  	
	 Oxford BioMedica plc:
  

John Dawson, Chief Executive Officer
  

Tim Watts, Chief Financial Officer
  
	  	Tel: +44 (0)1865 783 000
	 Financial and corporate communications enquiries:
  

Consilium Strategic Communications
  

Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton

 
	  	Tel: +44 (0)20 3709 5700

  

			
	Orchard Therapeutics Limited:	  	
	Sylvie Blanchier	  	Tel: +44 (0)20 3823 2149

 Notes to editors 

About Oxford BioMedica® 

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and
its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of
oncology, ophthalmology and CNS disorders. The 

  
 ***Confidential Treatment
Requested*** 
 Page | 39 

			
	28.11.2016	  	CONFIDENTIAL

  

 
Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell
therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk. 

About Orchard Therapeutics Ltd. 
 Orchard Therapeutics is
a clinical-stage biotechnology company dedicated to bringing transformative ex-vivo gene therapies to patients with serious and life-threatening orphan diseases. The company was recently named a Fierce
15 Company for 2016 by Fierce Biotech. For more information, visit www.orchard-tx.com 
 About Adenosine
Deaminase Deficiency Severe Combined Immunodeficiency (“ADA-SCID”) 

ADA-SCID is a rare inherited disorder of the immune system. The incidence of
ADA-SCID is estimated between 1 in every 375,000 - 660,000 live births, according to literature sources. ADA-SCID is caused by mutations in the gene encoding for the
enzyme adenosine deaminase, which result in a severe deficiency in white blood cells and life-threatening infections. In the absence of treatment, ADA-SCID is fatal within the first months of life. Despite
currently available treatment options, there remains significant need for therapies that reduce the mortality, morbidity and burden of disease on patients and families. 

About Mucopolysaccharidosis type-A (Sanfilippo Syndrome type A) 

Mucopolysaccharidosis type-A is a rare neurodegenerative lysosomal storage disease caused by mutations in the
sulfoglycosamine sulfohydrolase (SGSH) gene. There are no effective treatments for MPS-IIIA to date. The disease affects children in early life, with a progressive decline in cognitive and behavioural function
and a subsequent decline in motor function and results in severe dementia and early death, usually in the teens or early twenties. 

  
 ***Confidential Treatment
Requested*** 
 Page | 40 

			
	28.11.2016	  	CONFIDENTIAL

  

 SCHEDULE 5: COLLABORATION PLAN 

Collaboration Plan 24 November 2016 

Summary of work that either has been completed, is ongoing or is planned 

ADA-SCID 
  

	 	a.	 WORK COMPLETED 

	 	[***]	 

  

	 	b.	 WORK ONGOING 

	 	[***]	 

  

	 	c.	 FUTURE WORK 

	 	[***]	 

MPSIIIA 
  

	 	a.	 WORK ONGOING 

	 	[***]	 

  

	 	b.	 FUTURE WORK 

	 	[***]	 

  
 ***Confidential Treatment
Requested*** 
 Page | 41 

			
	28.11.2016	  	CONFIDENTIAL

  

 SCHEDULE 6: EXPERT DETERMINATION PROCEDURE 

Either Party may serve notice on the other (a “Referral Notice”) that it wishes to refer the disputed matter (the “Matter”)
to an expert (the “Expert”) for resolution in accordance with this Schedule 6. The Expert’s determination shall be binding on the Parties. 
  

	1.	 The Parties shall agree the identity of a single independent, impartial, appropriately qualified expert to
determine the Matter. In the absence of such agreement within [***] of the Referral Notice, upon request by either Party, the Expert shall be appointed by the ICC International Centre for ADR in accordance with the Rules for the Appointment of
Experts and Neutrals of the International Chamber of Commerce. 

  

	2.	 Within [***], both Parties shall exchange simultaneously statements of case, and each Party shall
simultaneously send a copy of its statement of case to the Expert. 

  

	3.	 Each Party may, [***] pursuant to paragraph 2 above, serve a reply to the other Party’s statement of case.
A copy of any such reply shall be simultaneously sent to the Expert. 

  

	4.	 The Expert shall make their decision on the Matter on the basis of the written statements and supporting
documentation provided by the Parties only and there shall be no oral hearing. The Expert shall issue their decision in writing within [***] pursuant to paragraph 3 above or, in the absence of receipt of any replies, within [***] pursuant to
paragraph 2 above. 

  

	5.	 The Expert’s charges shall be borne as determined by the Expert. 

  
 ***Confidential Treatment
Requested*** 
 Page | 42 

			
	28.11.2016	  	CONFIDENTIAL

  

 SCHEDULE 7: ORCHARD BACKGROUND PATENTS 

 

	 	[***]	 

  

	 	[***]	 

  
 ***Confidential Treatment
Requested*** 
 Page | 43 

			
	28.11.2016	  	CONFIDENTIAL

  

 SCHEDULE 8: KEY TERMS OF PHARMACOVIGILANCE AGREEMENT 

Each Party shall: 
  

	(a)	 ensure that it or its subcontractors shall have a Quality Management System for its Pharmacovigilance System
that complies with applicable regulations and guidelines and that deficiencies with regards to applicable regulations and guidelines are identified and mitigation plans are put in place and implemented in a reasonable timeframe. This should include
at a minimum appropriate metrics and measures of performance to provide evidence of the effectiveness of the Pharmacovigilance System. Must ensure that its own staff and any subcontractor staff are trained in the appropriate pharmacovigilance
procedures according to its SOPs. 

  

	(b)	 transmit to the other Party copies of [***] and [***] sent to Regulatory agencies relating to Relevant Products
for cases where [***], within specified expedited timelines. 

  

	(c)	 transmit to the other Party typically on a [***] basis (for discussion, pending recruitment rates etc.), to the
other Party a cumulative line-listing of all initial and follow-up of all [***]). Agreement to be made on the relevance of exchange of [***]. 

 

	(d)	 notify to the other Party any safety issue (urgent safety measure/restriction, product recall, signal
detection, amendments to Reference Safety Information etc.) promptly, for cases where [***]. 

  

	(e)	 collaborate on Platform Products [***] and duly provide to the other Party required information, as relevant
(e.g. patient exposure in clinical trials). 

	(f)	 promptly notify each other of any new findings (clinical or
non-clinical), which may imact the safety of the subjects of any clinical trials of the Relevant Products being conducted, for cases where OXB lentiviral vectors could be involved. 

 

	(g)	 promptly, transmit to the other Party any relevant safety question or request from a Health Authority relating
to the Relevant Products for cases [***]. In addition, each party to notify each other of any communication from the IRBs or ethics committees, DMC or any other external body regarding any safety concern relating to the Relevant Products for cases
where OXB lentiviral vectors could be involved 

  

	(h)	 agree to collaborate on a Risk Management Plan (RMP) for the Platform Products; such a RMP shall be set up as
required under the terms of any regulatory marketing approval.  

  

	(i)	 collaboration/meetings: The Parties agree to collaborate in good faith on all aspects and meet if relevant to
address safety aspects linked to the Platform Products. Frequency of meetings to be detailed. 

  
 ***Confidential Treatment
Requested*** 
 Page | 44 

 Amendment Letter 
  

			
	To:	  	Orchard Therapeutics Limited (“Orchard”)
		
	Address:	  	Birchin Court 20, Birchin Lane London EC3V 9DU
		
	With a
copy to:	  	[***]
		
		  	and
		
		  	[***]
		
		  	and
		
		  	[***]
		
		  	and
		
		  	 Ari B. Blaut, Esq.
 Sullivan & Cromwell
LLP
 125 Broad Street
 New York

NY 10004
 Facsimile: (212)291 9219

E-mail: blauta@sullcrom.com

 ***Confidential Treatment Requested*** 

 Date: 29 June 2017 

Dear Sirs, 
  

	 	1.	 We refer to the License and Development Agreement (the “LDA”) and the Supply Agreement (the
“SA”, together with the LDA, the “Agreements”) both dated 28 November 2016 and made between Oxford BioMedica (UK) Limited (the “Company”) and, Orchard (the Company and Orchard together
the “parties”). In particular (without limitation) we refer to clauses 12.7 of the LDA and 13.8 of the SA, which both include consents and provisions in relation to [***]. 

 

	 	2.	 We are informing you that [***]. 

 

	 	3.	 We request your consent to amend the Agreements such that: 

 

	 	a.	 reference to [***] is replaced with reference to [***]; 

 

	 	b.	 reference to [***] is replaced with reference to [***]; and 

 

	 	c.	 reference to the [***] is replaced with reference to the [***]. 

 

	 	4.	 All of the foregoing points a to c inclusive are herein collectively the “Amendments”.

  

	 	5.	 All other terms and conditions of the Agreements shall remain unchanged and in full force and effect mutatis
mutandis. 

  

	 	6.	 By your countersignature below, you acknowledge and agree: 

 

	 	a.	 to the Amendments; 

  

	 	b.	 [***]; 

  

	 	c.	 [***]; 

  

	 	d.	 you will pay all moneys hereafter becoming due to the Company in respect of the Agreements as directed in this
Letter and accept and will comply with the terms of this Letter and the provisions of the Agreements (as modified by this Letter); 

  

	 	e.	 you will send to [***] copies of any notices which you may give to the Company under the Agreements at the same
time as you send them to the Company; and 

  

	 	f.	 [***]. 

  

	 	7.	 The Company confirms that: 

 

	 	a.	 [***]; 

  

	 	b.	 [***]; and 

***Confidential Treatment Requested*** 

	 	c.	 any written notice or instructions given to you by [***] in accordance with this Letter shall be conclusive
(except for the avoidance of doubt, in relation to the Amendments). 

  

	 	8.	 This Letter shall be governed by English Law. The English Courts shall have exclusive jurisdiction to deal with
any disputes which have arisen or may arise out of or in connection with this Letter. 

  

	 	9.	 This Letter may be executed in any number of counterparts and has the same effect as if the signatures on the
counterparts were on a single copy of this Letter. 

  

	 	10.	 Kindly sign the enclosed counterpart and return by post to Oxford BioMedica (UK) Ltd, Windrush Court, Transport
Way, Oxford 0X4 6LT for the attention of [***], with a copy to: [***]. 

 Yours faithfully, 

/s/ Timothy Watts 
 for and on behalf of 

Oxford BioMedica (UK) Limited 
 Acknowledged and agreed, 

/s/ Nicolas Koebel 
 Orchard Therapeutics Limited 

Date: 03 July 2017 
 ***Confidential Treatment
Requested*** 

 OXFORD BIOMEDICA 

CONFIDENTIAL 
  

 SECOND AMENDMENT OF THE LICENCE AND DEVELOPMENT AGREEMENT 

BETWEEN 
 Oxford BioMedica
(UK) Limited 
 & 
 Orchard
Therapeutics Limited 
 This second amendment of the licence and development agreement (the “Second Amendment”) is made this 31st day of May 2018 (the “Second Amendment Effective Date”) 
 BETWEEN 

Oxford BioMedica (UK) Ltd, a company incorporated in England and Wales whose registered office address is at Windrush Court, Transport Way, Oxford, OX4
6LT, United Kingdom, and other affiliated members of the Oxford BioMedica pic group of companies, (hereinafter “BioMedica”). 
 AND 

Orchard Therapeutics Limited, a company incorporated in England whose registered office is at 108 Cannon Street, London, EC4N 6EU, United Kingdom
(hereinafter “Orchard”) 
 WHEREAS BioMedica and Orchard entered into a licence and development agreement dated 28 November
2016 which was amended on 3 July 2017 (together “the Agreement”) and wish to amend the Agreement as shown below. 
 NOW IT IS
AGREED as follows: 
  

	1.	 Clause 1.1 of the Agreement shall be amended by adding the following to the end of clause 1.1(j):

 (iv) Technology Access Fee for cell line development. 

 

	2.	 Clause 1.1 of the Agreement shall be further amended by adding the following definition to clause 1.1:

 “Technology Access Fee” means a fee for utilising BioMedica’s [***], which fee shall be [***] (or
other such amount agreed between the Parties in writing or outlined in a statement of work signed by the Parties). 
  

	3.	 A new Clause 4.7A shall be added after Clause 4.7 as follows: 

 

	 	4.7A	 Technology Access Fee 

 

	 	(a)	 It is agreed by the Parties that the Technology Access Fee shall only be charged to Orchard by BioMedica when
the [***] has actually been used by BioMedica in the performance of activities set out in the Collaboration Plan. 

  

	 	(b)	 If BioMedica commences the use of the [***] but any of the following: 

 

	 	i.	 a system failure (including, without limitation, mechanical failure, software error or tissue culture
contamination); or 

  

	 	ii.	 any act or omission of BioMedica; or 

 

	 	iii.	 force majeure (Clause 12.1); 

results in the inability of BioMedica to use the [***] in such [***] to complete the proposed stage of work that was scheduled to be
undertaken, then BioMedica will waive the 

  
 ***Confidential Treatment
Requested*** 
 Page 1 of 4 

 OXFORD BIOMEDICA 

CONFIDENTIAL 
  

	 	
Technology Access Fee for such [***] and will (subject to the provisions of sub-paragraph (c) below) reschedule such work on an expedited basis to
minimize delay in completion of such work and the impact on the Collaboration Plan. For the avoidance of doubt, the Technology Access Fee will be charged for the rescheduled [***] work provided it has not been previously paid. 

 

	 	(c)	 In the event that access to the [***] needs to be rescheduled pursuant to sub-paragraph (b) above,
BioMedica shall promptly consult with Orchard to agree upon the timing of any rescheduled work. In the event that the Parties are not able to agree upon an appropriate time slot for the rescheduled work on the [***], Orchard shall have the right to
cancel such work as well as any other scheduled work contemplated by the Collaboration Plan involving use of the [***] and the Parties shall be required to promptly agree a revision to the Collaboration Plan to take account of such cancellation.

  

	4.	 Clause 4.8(b) shall be amended by the addition of the language underlined below as follows:

  

	 	    	 Within [***] after [***], BioMedica shall provide Orchard with a statement of the activities performed under
the Collaboration Plan and the Collaboration Costs incurred by it in such [***] (each, a “Collaboration Costs Report”) together with an invoice for such Collaboration Costs. Notwithstanding the previous sentence but subject to the
provisions of Clause 4.7A above, the Technology Access Fee will be invoiced by BioMedica within [***] after the end of each [***] that the Technology Access Fee is applied. Orchard shall pay such invoices within [***] after receipt of such
invoice. 

  

	5.	 Clause 12.4 (Notices and Other Communications) shall be amended by deleting the current notice provisions for
Orchard and replacing them with the following: 

 For Orchard 

For the attention of: [***] 

Address: Orchard Therapeutics Limited, 108 Cannon Street, London EC4N 6EU, UK 

With a copy to: General Counsel, Orchard Therapeutics Limited, 108 Cannon Street, London EC4N 6EU, UK 

 

	6.	 Schedule 5 (the Collaboration Plan) of the Agreement shall be deleted in its entirety and replaced with the
updated Schedule 5 (Collaboration Plan) attached as Exhibit A to this Second Amendment. 

  

	5.	 Miscellaneous 

  

	5.1	 This Second Amendment shall become effective on the Second Amendment Effective Date. 

 

	5.2	 Except as specifically amended by this Second Amendment, the terms and conditions of the Agreement shall remain
in full force and effect. All capitalized terms used but not otherwise defined In this Second Amendment shall have the meanings given to such terms in the Agreement. 

 

	5.3	 This Second Amendment shall be governed by the laws of England as set forth in clause 12.14 of the Agreement.

  
 ***Confidential Treatment
Requested*** 
 Page 2 of 4 

 OXFORD BIOMEDICA 

CONFIDENTIAL 
  

					
	
			
	Signed for and on behalf of the Orchard Therapeutics Limited	 	
                
	 	
			
	 /s/ Stewart Craig
	 		 	 Date:
31ST MAY 2018

			
	 Print name: Stewart Craig
	 		 	
			
	 Position: Chief Manufacturing Officer
	 		 	
			
	 Signed for and on behalf of Oxford BioMedica (UK) Ltd
	 		 	
			
	 /s/ James Miskin
	 		 	 Date: 01 JUN 2018

			
	 Print name: James Miskin
	 		 	
			
	 Position: CTO
	 		 	

  
 ***Confidential Treatment
Requested*** 
 Page 3 of 4 

 OXFORD BIOMEDICA 

CONFIDENTIAL 
  

 EXHIBIT A 

SCHEDULE 5: COLLABORATION PLAN 

Collaboration Plan updated 31st May 2018 

Below is a summary of work that either has been completed, is ongoing or is planned under Schedule 5 Collaboration Plan of Licence and Development Agreement
between Oxford BioMedica (UK) Ltd and Orchard Therapeutics Ltd dated 28th November 2016 (as amended from time to time). 

ADA-SCID 
  

	 	a.	 WORK COMPLETED 

[***] 
  

	 	b.	 WORK ONGOING 

[***] 
  

	 	c.	 FUTURE WORK 

[***] 
 MPSIIIA 

 

	 	a.	 WORK COMPLETED 

[***] 
  

	 	b.	 WORK ONGOING 

[***] 
  

	 	c.	 FUTURE WORK: 

[***] 
 [***] 

  
 ***Confidential Treatment
Requested*** 
 Page 4 of 4 

 OXFORD BIOMEDICA 

CONFIDENTIAL 
  

 THIRD AMENDMENT OF THE LICENCE AND DEVELOPMENT AGREEMENT BETWEEN 

Oxford BioMedica (UK) Limited 

& 
 Orchard Therapeutics Limited

 This third amendment of the licence and development agreement (the “Third Amendment”) is made this 9th day of July 2018 (the “Third Amendment Effective Date”) 
 BETWEEN 

Oxford BioMedica (UK) Ltd, a company incorporated in England and Wales whose registered office address is at Windrush Court, Transport Way, Oxford, 0X4
6LT, United Kingdom, and other affiliated members of the Oxford BioMedica pic group of companies, (hereinafter “BioMedica”). 
 AND 

Orchard Therapeutics Limited, a company incorporated in England whose registered office is at 108 Cannon Street, London, EC4N 6EU, United Kingdom
(hereinafter “Orchard”) 
 WHEREAS BioMedica and Orchard entered into a licence and development agreement dated 28 November
2016 which was amended on 3 July 2017 (together “the Agreement”) and wish to amend the Agreement as shown below. 
 NOW IT IS
AGREED as follows: 
  

	1.	 Schedule 2 of the agreement shall be replaced in its entirety with the version attached hereto at Exhibit A.
The purpose of the amendment is to include two new approved subcontractors, [***] and [***]. 

  

	2.	 Miscellaneous 

  

	2.1	 This Third Amendment shall become effective on the Third Amendment Effective Date. 

 

	2.2	 Except as specifically amended by this Third Amendment, the terms and conditions of the Agreement shall remain
in full force and effect. All capitalized terms used but not otherwise defined in this Third Amendment shall have the meanings given to such terms in the Agreement. 

 

	2.3	 This Third Amendment shall be governed by the laws of England as set forth in clause 12.14 of the Agreement.

 Signatures follow on next page 

  
 ***Confidential Treatment
Requested*** 
 Page 1 of 3 

 OXFORD BIOMEDICA 

CONFIDENTIAL 
  

					
	Signed for and on behalf of the Orchard Therapeutics Limited	 		  	
			
	 /s/ Stewart Craig
	 	
                
	  	Date: 12 Jul 2018
			
	Print name: Stewart Craig	 		  	
			
	Position: CMO	 		  	
			
	Signed for and on behalf of Oxford BioMedica (UK) Ltd	 		  	
			
	 /s/ Kyriacos Mytrphanous
	 		  	Date: 13 JUL 2018
			
	Print name: K. Mitrophanous	 		  	
			
	Position: CSO	 		  	

  
 ***Confidential Treatment
Requested*** 
 Page 2 of 3 

 OXFORD BIOMEDICA 

CONFIDENTIAL 
  

 EXHIBIT A 

SCHEDULE 2: APPROVED SUBCONTRACTORS 
  

			
	 Name
	  	 Service

		
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  
 ***Confidential Treatment
Requested*** 
 Page 3 of 3 

 CONFIDENTIAL 

OXFORD BIOMEDICA(UK) LIMITED 

and 
 ORCHARD
THERAPEUTICS LIMITED 
  
  

LICENCE AND DEVELOPMENT AGREEMENT 

Amendment #4 
  

 

  
 ***Confidential Treatment
Requested*** 
 Page | 1 

			
		  	CONFIDENTIAL

  

 BETWEEN: 
  

	(1)	 OXFORD BIOMEDICA (UK) LIMITED, a company incorporated in England and registered under number 03028927,
whose registered office is at Windrush Court, Transport Way, Oxford, 0X4 6LT (“BioMedica”); and 

  

	(2)	 ORCHARD THERAPEUTICS LIMITED, a company incorporated in England and registered under number 09759506,
whose registered office is at 108b Cannon Street, EC4N 6EU London (“Orchard”). 

 BACKGROUND: 

 

	(A)	 Orchard has appointed BioMedica to perform development activities and to manufacture and supply lentiviral
vectors taken a licence under certain intellectual property of BioMedica on the terms of this Agreement under a License and Development Agreement executed on the 28th of November 2017
(“Agreement”). 

  

	(B)	 The Agreement contains provisions regarding the issue of equity to BioMedica upon achievement of Milestones
described in Schedule 3 of the Agreement. 

  

	(C)	 At the Joint Steering Committee dated 15 June 2018 both parties verbally agreed to a revision of certain
of the milestones in the Agreement, and the parties now wish to formally amend the provisions relating to the aforementioned milestones in accordance with the terms of this fourth amendment to the Agreement (“Fourth Amendment”).

 OPERATIVE PROVISIONS 
  

	1.1	 Milestone 2 and Milestone 4 in Schedule 3 of the Agreement are amended as follows: 

Milestone 2 
 Orchard shall issue to BioMedica
94,231 ordinary shares in Orchard upon the achievement, as determined by the Steering Committee pursuant to clause 2.6, of [***]. 
 Milestone 4

 Orchard shall issue to BioMedica 94,231 ordinary shares in Orchard upon the achievement, as determined by the Steering Committee pursuant to
clause 2.6, of [***]. 
  

	1.2	 Notwithstanding the date of execution of this amendment, the parties agree that this amendment shall be deemed
effective as of 15 June 2018. 

  

	1.3	 Except as specifically amended by this Fourth Amendment, the terms and conditions of the Agreement shall remain
in full force and effect. All capitalized terms used but not otherwise defined in this Fourth Amendment shall have the meanings given to such terms in the Agreement. 

 

	1.4	 This Fourth Amendment shall be governed by the laws of England as set forth in clause 12.14 of the Agreement.

  
 ***Confidential Treatment
Requested*** 
 Page | 2 

			
		  	CONFIDENTIAL

  

			
	For and on behalf of	  	For and on behalf of
		
	OXFORD BIOMEDICA (UK) LIMITED:	  	ORCHARD THERAPEUTICS LIMITED:
		
	Signature	  	Signature
		
	/s/ Stuart Paynter	  	/s/ Nicolas Koebel
		
	Print name	  	Print name
	Stuart Paynter	  	Nicolas Koebel
		
	Job title	  	Job title
	CFO	  	Chief of Staff and Head of Program Management
		
	Date	  	Date
		  	11 September 2018

  
 ***Confidential Treatment
Requested*** 
 Page | 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}]]